EP3126354A1 - Halogenated quinazolin-thf-amines as pde1 inhibitors - Google Patents

Halogenated quinazolin-thf-amines as pde1 inhibitors

Info

Publication number
EP3126354A1
EP3126354A1 EP15713186.3A EP15713186A EP3126354A1 EP 3126354 A1 EP3126354 A1 EP 3126354A1 EP 15713186 A EP15713186 A EP 15713186A EP 3126354 A1 EP3126354 A1 EP 3126354A1
Authority
EP
European Patent Office
Prior art keywords
amine
methoxy
quinazolin
stereoisomer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15713186.3A
Other languages
German (de)
French (fr)
Other versions
EP3126354B1 (en
Inventor
Jan Kehler
Lars Kyhn Rasmussen
Morten LANGGÅRD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to RS20200239A priority Critical patent/RS60017B1/en
Priority to PL15713186T priority patent/PL3126354T3/en
Priority to SI201531112T priority patent/SI3126354T1/en
Publication of EP3126354A1 publication Critical patent/EP3126354A1/en
Application granted granted Critical
Publication of EP3126354B1 publication Critical patent/EP3126354B1/en
Priority to HRP20200369TT priority patent/HRP20200369T1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Definitions

  • the present invention provides compounds that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
  • the present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
  • cyclic Nucleotides cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) play a major role in intracellular signal transduction cascade, by regulating cN-dependent protein kinases (PKA and PKG), EPACs (Exchange Protein Activated by cAMP), phosphoprotein phosphatases, and/or cN-gated cation channels.
  • PKA and PKG cN-dependent protein kinases
  • EPACs Exchange Protein Activated by cAMP
  • phosphoprotein phosphatases and/or cN-gated cation channels.
  • Intracellular concentrations of cAMP and cGMP are strictly regulated by the rate of biosynthesis by cyclases and by the rate of degradation by phosphodiesterases (PDEs, EC 3.1 .4.17).
  • PDEs are bimetallic hydrolases that inactivate cAMP/cGMP by catalytic hydrolysis of the 3'-ester bond, forming the inactive 5'-monophosphate. Since PDEs provide the only means of degrading the cyclic nucleotides cAMP and cGMP in cells, PDEs play an essential role in cyclic nucleotide signalling.
  • PDEs The catalytic activities of PDEs provide for breakdown of cNs over a spectrum of concentrations in all cells, and their varied regulatory mechanisms provide for integration and crosstalk with myriad signalling pathways. Particular PDEs are targeted to discrete compartments within cells where they control cN level and sculpt microenvironments for a variety of cN signalosomes (Sharron H. Francis, Mitsi A. Blount, and Jackie D. Corbin. Physiol Rev 201 1 , 91 : 651-690).
  • the PDE families can be divided into three groups: 1 ) The cAMP-specific PDEs, which include PDE4, PDE7, and PDE8, 2) the cGMP-selective enzymes PDE5 and PDE9, and 3) the dual-substrate PDEs, PDE1 , PDE2, PDE3, as well as PDE10 and PDE1 1 .
  • the cAMP-specific PDEs which include PDE4, PDE7, and PDE8, 2) the cGMP-selective enzymes PDE5 and PDE9, and 3) the dual-substrate PDEs, PDE1 , PDE2, PDE3, as well as PDE10 and PDE1 1 .
  • calmodulin-stimulated PDE PDE1 is unique in that it is Ca 2+ -dependently regulated via calmodulin (CaM, a 16 kDa Ca 2+ -binding protein) complexed with four Ca 2+ (for review, Sharron H. Francis, Mitsi A. Blount, and Jackie D. Corbin. Physiol Rev 201 1 , 91 : 651-690).
  • CaM Ca 2+
  • CaM CaM, a 16 kDa Ca 2+ -binding protein
  • the PDE1 family is encoded by three genes: PDE1A (mapped on human chromosome 2q32), PDE1 B (human chromosome location, hcl: 12q13) and PDE1 C (hcl: 7p14.3). They have alternative promoters and give rise to a multitude of proteins by alternative splicing which differ in their regulatory properties, substrate affinities, specific activities, activation constants for CaM, tissue distribution and molecular weights. More than 10 human isoforms are identified. Their molecular weights vary from 58 to 86 kDa per monomer. The N-terminal regulatory domain that contains two Ca 2 7CaM binding domains and two phosphorylation sites differentiate their corresponding proteins and modulate their biochemical functions.
  • PDE1 is a dual substrate PDE and the PDE1 C-subtype has equal activity towards cAMP and cGMP (Km « 1 -3 ⁇ ), whereas the subtypes PDE1A and PDE1 B has a preference for cGMP (Km for cGMP * 1 -3 ⁇ and for cAMP * 10-30 ⁇ ).
  • the PDE1 subtypes are highly enriched in the brain and located especially in the striatum (PDE1 B), hippocampus (PDE1A) and cortex (PDE1A) and this localization is conserved across species (Amy Bernard et al. Neuron 2012, 73, 1083-1099).
  • PDE1A is present mainly in deep cortical layers 5 and 6 (output layers), and used as a specificity marker for the deep cortical layers.
  • PDE1 inhibitors enhance the levels of the second messenger cNs leading to enhanced neuronal excitability.
  • PDE1 is a therapeutic target for regulation of intracellular signalling pathways, preferably in the nervous system and PDE1 inhibitors can enhance the levels of the second messengers cAMP/cGMP leading to modulation of neuronal processes and to the expression of neuronal plasticity-related genes, neurotrophic factors, and neuroprotective molecules.
  • PDE1 inhibitors are useful in diseases that may be alleviated by the enhancement of progesterone-signalling such as female sexual dysfunction e.g. WO-2010065153.
  • SUMMARY OF THE INVENTION PDE1 enzymes are expressed in the Central Nervous System (CNS), making this gene family an attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders.
  • CNS Central Nervous System
  • the compounds of the invention may offer alternatives to current marketed treatments for neurodegenerative and/or psychiatric disorders, which are not efficacious in all patients. Hence, there remains a need for alternative methods of treatment.
  • the objective of the present invention is to provide compounds that are PDE1 inhibitors, and as such are useful to treat neurodegenerative disorders and psychiatric disorders.
  • the compounds are selective PDE1 inhibitors. Accordingly, the present invention relates to compounds of formula (I)
  • Ri is selected from the group consisting of H and Ci- C3 alkyi, wherein the alkyi optionally may be substituted one, two or three times with fluorine;
  • R2 is selected from the group consisting of H and Ci-C 4 alkyi, wherein the Ci-C 4 alkyi optionally is substituted one or more times with one or more substituents
  • R 3 is selected from the group consisting of H and C1-C6 alkyi, wherein the C1-C6 alkyi optionally is substituted one or more times with one or more substituents
  • R and R 5 independently of each other are selected from the group consisting of H, C1-C6 alkyi, optionally is substituted one or more times with one or more substituents, C3-C6 cycloalkyl, fluorine, chlorine, hydroxy and alkoxy
  • R 6 and R 7 independently of each other are selected from the group consisting of H and C1-C6 alkyi, wherein the C1-C6 alkyi optionally is substituted one or more times with one or more substituents
  • Rs and Rg independently of each other are selected from the group consisting of H and C1-C6 alkyl, wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents, and pharmaceutically acceptable acid addition salts of Compound I, racemic mixtures of Compound I, or the corresponding enantiomer and/or diastereo-isomer of Compound I, and polymorphic forms of Compound I as well as tautomeric forms of Compound I.
  • Ri is selected from the group consisting of H and C1-C3 alkyl, wherein the alkyl optionally may be substituted one, two or three times with fluorine;
  • R2 is selected from the group consisting of H and Ci-C 4 alkyl wherein R 2 , when R 2 is a Ci-C 4 alkyl, may form a saturated five membered aliphatic ring with R 9 wherein the Ci-C 4 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of phenyl, monocyclic 5- or 6-membered heteroaryl, C3-C6 cycloalkyi, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl;
  • R3 is selected from the group consisting of H and C1-C6 alkyl wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of phenyl, monocyclic 5- or 6-membered heteroaryl, C3-C6 cycloalkyi, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl; R and R 5 independently of each other are selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyi, fluorine, chlorine, hydroxy and alkoxy of the form -OR10 wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of phenyl, monocyclic 5- or 6-membered heteroaryl, C3-C6 cycloalkyi, fluorine, chlorine, and alkoxy of the form
  • R6 and R 7 independently of each other are selected from the group consisting of H and C1-C6 alkyl wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of C3-C6 cycloalkyi, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl; Rs and Rg independently of each other are selected from the group consisting of H and C1-C6 alkyl wherein R 9 , when R 9 is a C1-C6 alkyl, may form a saturated aliphatic five membered ring with R 2 wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of C3-C6 cycloalkyl, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl; and/or pharmaceutical
  • R 2 is H or -CH 3.
  • (E8) of (E1 ) Ri is substituted one time with fluorine. In an embodiment (E9) of (E1 ) Ri is substituted two times with fluorine. In an embodiment (E10) of (E1 ) Ri is substituted three times with fluorine. In an embodiment (E1 1 ) of (E1 ) X is fluorine. In an embodiment (E12) of (E1 ) X is chlorine.
  • the compound in an embodiment (E14) of any of (E1 ) to (E13) the compound is a PDE1A inhibitor. In an embodiment (E15) of any of (E1 ) to (E13) the compound is a PDE1 B inhibitor.
  • the compound is a PDE1 C inhibitor.
  • the compound of any of (E1 ) to (E16) is for use as a medicament.
  • the compound of any of (E1 ) to (E16) is use in the treatment of attention-deficit hyperactivity disorder (ADHD)
  • Embodiment (E19) A pharmaceutical composition comprising the compound of any of (E1 ) to (E16) and one or more pharmaceutically acceptable carriers.
  • Embodiment (E20) A pharmaceutical composition according to (E19) for use in a method of treatment of attention-deficit/hyperactivity disorder (ADHD)
  • Embodiment (E22) A compound of any one of (E1 ) to (E16) for the preparation of a medicament for use in the treatment of attention-deficit/hyperactivity disorder (ADHD).
  • Embodiment (E24) A pharmaceutical composition according to (E19) for use in a method of treatment of neurodegenerative disorder.
  • Embodiment (E25) A compound of any one of (E1 ) to (E16) for use in a method for the treatment of neurodegenerative disorder.
  • Embodiment (E26) A compound of any one of (E1 ) to (E16) for the preparation of a medicament for use in the treatment of neurodegenerative disorder.
  • Embodiment (E27) A method of treating a subject suffering of a neurodegenerative disorder which method comprises administering an effective amount of a compound of any one (E1 ) to (E16).
  • the neurodegenerative disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease and Huntington's Disease or for the treatment of a psychiatric disorder such as Attention Deficit hyperactivity Disorder (ADHD), depression, narcolepsy, cognitive impairment and cognitive impairment associated with schizophrenia (CIAS).
  • ADHD Attention Deficit hyperactivity Disorder
  • depression depression
  • narcolepsy cognitive impairment and cognitive impairment associated with schizophrenia
  • Embodiment (E29) Use of a compound of any of claims 1 -7 in the manufacture of a medicament for the treatment of a neurodegenerative disorder, such as Alzheimer's Disease, Parkinson's Disease and Huntington's Disease or for the treatment of a psychiatric disorder such as Attention Deficit hyperactivity Disorder (ADHD), depression, narcolepsy, cognitive impairment and cognitive impairment associated with schizophrenia (CIAS) or a brain disease like restless leg syndrome.
  • a neurodegenerative disorder such as Alzheimer's Disease, Parkinson's Disease and Huntington's Disease
  • a psychiatric disorder such as Attention Deficit hyperactivity Disorder (ADHD), depression, narcolepsy, cognitive impairment and cognitive impairment associated with schizophrenia (CIAS) or a brain disease like restless leg syndrome.
  • ADHD Attention Deficit hyperactivity Disorder
  • depression depression
  • narcolepsy cognitive impairment and cognitive impairment associated with schizophrenia
  • cognitive impairment and cognitive impairment associated with schizophrenia or a brain disease like restless leg syndrome.
  • Embodiment (E30) In an embodiment (E30) of (E1 ) Ri is H.
  • the PDE1 isozyme family includes numerous splice variant PDE1 isoforms. It has three subtypes, PDE1A, PDE1 B and PDE1 C which divide further into various isoforms.
  • PDE1 and PDE1 enzymes are synonymous and refer to PDE1A, PDE1 B and PDE1 C enzymes as well as their isoforms.
  • halo and halogen are used interchangeably and refer to fluorine, chlorine, bromine or iodine.
  • C1-C3 alkyl refers to a straight-chain or branched saturated hydrocarbon having from one to six carbon atoms, inclusive.
  • Examples of such groups include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1 -butyl, and n- hexyl.
  • C3-C6 cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • alkoxy refers to a straight-chain or branched saturated alkoxy group having from one to six carbon atoms, inclusive, with the open valency on the oxygen. Examples of such groups include, but are not limited to, methoxy, ethoxy, n- butoxy, 2-methyl-pentoxy and n-hexyloxy.
  • aryl refers to a phenyl ring, optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy or halo(Ci-Ce)alkyl as defined above.
  • heteroaryl refers to monocyclic- or polycyclic aromatic ring comprising carbon atoms, hydrogen atoms, and one or more heteroatoms, preferably, 1 to 3 heteroatoms, independently selected from nitrogen, oxygen, and sulfur.
  • heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1 ,2,3,)- and (1 ,2,4)-triazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, furanyl, thiophenyl, isoxazolyl, thiazolyl, isoxazolyl, and oxazolyl.
  • a heteroaryl group can be unsubstituted or substituted with one or two suitable substituents.
  • the heteroaryl of this invention is a monocyclic 5 or 6 membered heteroaryl, wherein the ring comprises 2 to 5 carbon atoms and 1 to 3 heteroatoms, referred to herein as "monocyclic 5 or 6 membered heteroaryl".
  • a compound is considered to be a PDE1 inhibitor if the amount required to reach the IC 5 o level of PDE1 B is 5 micro molar or less, preferably less than 4 micro molar, such as 3 micro molar or less, more preferably 2 micro molar or less, such as 1 micro molar or less, in particular 500 nM or less.
  • the required amount of PDE1 inhibitor required to to reach the IC 5 o level of PDE1 B is 400nM or less, such as 300 nM or less, 200nM or less, 100 nM or less, or even 80 nM or less, such as 50 nM or less, for example 25 nM or less.
  • the present invention also comprises pharmaceutically acceptable salts of the compounds.
  • Such salts include acid addition salts.
  • Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like.
  • suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p- toluenesulfonic acids, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline and the
  • the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
  • the term "therapeutically effective amount" of a compound means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and/or its complications in a therapeutic intervention comprising the administration of said compound.
  • An amount adequate to accomplish this is defined as “therapeutically effective amount”.
  • Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician.
  • treatment means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder.
  • the term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to relief the symptoms and complications, and/or to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications.
  • prophylactic (preventive) and therapeutic (curative) treatments are two separate aspects of the invention.
  • the patient to be treated is preferably a mammal, in particular a human being.
  • the present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier or diluent.
  • the present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of one of the specific compounds disclosed in the Experimental Section herein and a pharmaceutically acceptable carrier or diluent.
  • the compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers, diluents or excipients, in either single or multiple doses.
  • pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 21 th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 2005.
  • compositions may be specifically formulated for administration by any suitable route such as oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) routes. It will be appreciated that the route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient.
  • compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, the compositions may be prepared with coatings such as enteric coatings or they may be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art.
  • Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
  • Pharmaceutical compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use.
  • Other suitable administration forms include, but are not limited to, suppositories, sprays, ointments, creams, gels, inhalants, dermal patches and implants.
  • Typical oral dosages range from about 0.001 to about 100 mg/kg body weight per day. Typical oral dosages also range from about 0.01 to about 50 mg/kg body weight per day. Typical oral dosages further range from about 0.05 to about 10 mg/kg body weight per day. Oral dosages are usually administered in one or more dosages, typically, one to three dosages per day. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art. The formulations may also be presented in a unit dosage form by methods known to those skilled in the art. For illustrative purposes, a typical unit dosage form for oral administration may contain from about 0.01 to about 1000 mg, from about 0.05 to about 500 mg, or from about 0.5 mg to about 200 mg.
  • parenteral routes such as intravenous, intrathecal, intramuscular and similar administration
  • typical doses are in the order of half the dose employed for oral administration.
  • the present invention also provides a process for making a pharmaceutical composition
  • a process for making a pharmaceutical composition comprising mixing a therapeutically effective amount of a compound of formula (I) and at least one pharmaceutically acceptable carrier or diluent.
  • the compound utilized in the aforementioned process is one of the specific compounds disclosed in the Experimental Section herein.
  • the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
  • One example is an acid addition salt of a compound having the utility of a free base.
  • a compound of formula (I) contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of formula (I) with a molar equivalent of a pharmaceutically acceptable acid.
  • suitable organic and inorganic acids are described above.
  • solutions of the compounds of formula (I) in sterile aqueous solution aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the compounds of formula (I) may be readily incorporated into known sterile aqueous media using standard techniques known to those skilled in the art.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • solid carriers include lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose.
  • liquid carriers include, but are not limited to, syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the pharmaceutical compositions formed by combining the compounds of formula (I) and a pharmaceutically acceptable carrier are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
  • the formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and optionally a suitable excipient.
  • the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in- water or water-in-oil liquid emulsion.
  • the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it may be in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but will range from about 25 mg to about 1 g per dosage unit.
  • the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • compositions of the invention may be prepared by conventional methods in the art.
  • tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tableting machine prepare tablets.
  • adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatin, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colorings, flavorings, preservatives etc. may be used provided that they are compatible with the active ingredients.
  • the compounds of formula (I) are PDE1 enzyme inhibitors and as such are useful to treat associated neurological and psychiatric disorders.
  • the invention thus provides a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof, as well as a pharmaceutical composition containing such a compound, for use in the treatment of a neurodegenerative disorder, psychiatric disorder or drug addiction in mammals including humans; wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit/hyperactivity disorder; and age- related cognitive decline; and wherein the psychiatric disorder is selected from the group consisting of schizophrenia, for example of the paranoid, disorganized, catatonic, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder,
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be used as the sole active ingredient or in combination with one or more other drugs in the treatment of diseases or conditions for which the compounds of the present invention have utility, where the combination of the drugs together are safer or more effective than either drug alone.
  • the compounds of the present invention may be used in combination with one or more other drugs that treat, prevent, control, ameliorate, or reduce the risk of side effects or toxicity of the compounds of the present invention.
  • Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with the compounds of the present invention.
  • the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to the compounds of the present invention.
  • the combinations may be administered as part of a unit dosage form combination product, or as a kit or treatment protocol wherein one or more additional drugs are administered in separate dosage forms as part of a treatment regimen.
  • the present invention provides a method of treating a mammal, including a human, suffering from a neurodegenerative disorder selected from a cognition disorder or movement disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I).
  • This invention further provides a method of treating a neurodegenerative disorder or condition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula (I) effective in inhibiting PDE1 .
  • This invention also provides a method of treating a subject suffering from a psychiatric disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I).
  • Examples of psychiatric disorders include, but are not limited to, Attention Deficit Hyperactivity Disorder (ADHD) schizophrenia, for example of the paranoid, disorganized, catatonic, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the depressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type; and the anxiety disorder is selected from panic disorder; agoraphobia; a specific phobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; acute stress disorder; and generalized anxiety disorder.
  • ADHD Attention Deficit Hyperactivity Disorder
  • schizophrenia for example of the paranoid, disorganized, catatonic, undifferentiated, or residual type
  • schizophreniform disorder
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may advantageously be administered in combination with at least one neuroleptic agent (which may be a typical or an atypical antipsychotic agent) to provide improved treatment of psychiatric disorders such as schizophrenia.
  • the combinations, uses and methods of treatment of the invention may also provide advantages in treatment of patients who fail to respond adequately or who are resistant to other known treatments.
  • the present invention thus provides a method of treating a mammal suffering from a psychiatric disorder, such as schizophrenia, which method comprises administering to the mammal a therapeutically effective amount of a compound of formula (I), either alone or as combination therapy together with at least one neuroleptic agent.
  • neuroleptic agent refers to drugs, which have the effect on cognition and behaviour of antipsychotic agent drugs that reduce confusion, delusions, hallucinations, and psychomotor agitation in patients with psychoses.
  • neuroleptic agents include, but are not limited to: typical antipsychotic drugs, including phenothiazines, further divided into the aliphatics, piperidines, and piperazines, thioxanthenes (e.g., cisordinol), butyrophenones (e.g., haloperidol), dibenzoxazepines (e.g., loxapine), dihydroindolones (e.g., molindone), diphenylbutylpiperidines (e.g., pimozide), and atypical antipsychotic drugs, including benzisoxazoles (e.g., risperidone), sertindole, olan
  • Particularly preferred neuroleptic agents for use in the invention are sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.
  • the present invention further provides a method of treating a subject suffering from a cognition disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I).
  • cognition disorders that can be treated according to the present invention include, but are not limited to, Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit hyperactivity disorder; and age-related cognitive decline.
  • This invention also provides a method of treating a movement disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I).
  • movement disorders that can be treated according to the present invention include, but are not limited to, Huntington's disease and dyskinesia associated with dopamine agonist therapy.
  • This invention further provides a method of treating a movement disorder selected from Parkinson's disease and restless leg syndrome, which comprises administering to the subject a therapeutically effective amount of a compound of formula (I).
  • This invention also provides a method of treating a mood disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I).
  • mood disorders and mood episodes that can be treated according to the present invention include, but are not limited to, major depressive episode of the mild, moderate or severe type, a manic or mixed mood episode, a hypomanic mood episode; a depressive episode with a typical features; a depressive episode with melancholic features; a depressive episode with catatonic features; a mood episode with postpartum onset; post-stroke depression; major depressive disorder; dysthymic disorder; minor depressive disorder; premenstrual dysphoric disorder; post-psychotic depressive disorder of schizophrenia; a major depressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia; a bipolar disorder, for example bipolar I disorder, bipolar II disorder, and cyclothymic disorder.
  • a mood disorder is a psychiatric disorder.
  • This invention further provides a method of treating a disorder comprising as a symptom a deficiency in attention and/or cognition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula (I) effective in treating said disorder.
  • a "neurodegenerative disorder or condition” refers to a disorder or condition that is caused by the dysfunction and/or death of neurons in the central nervous system.
  • the treatment of these disorders and conditions can be facilitated by administration of an agent which prevents the dysfunction or death of neurons at risk in these disorders or conditions and/or enhances the function of damaged or healthy neurons in such a way as to compensate for the loss of function caused by the dysfunction or death of at-risk neurons.
  • neurotrophic agent refers to a substance or agent that has some or all of these properties.
  • neurodegenerative disorders and conditions that can be treated according to the present invention include, but are not limited to, Parkinson's disease; Huntington's disease; dementia, for example Alzheimer's disease, multi- infarct dementia, AIDS-related dementia, and Fronto temperal Dementia; neurodegeneration associated with cerebral trauma; neurodegeneration associated with stroke, neurodegeneration associated with cerebral infarct; hypoglycemia- induced neurodegeneration; neurodegeneration associated with epileptic seizure; neurodegeneration associated with neurotoxin poisoning; and multi-system atrophy.
  • Parkinson's disease Huntington's disease
  • dementia for example Alzheimer's disease, multi- infarct dementia, AIDS-related dementia, and Fronto temperal Dementia
  • neurodegeneration associated with cerebral trauma neurodegeneration associated with stroke, neurodegeneration associated with cerebral infarct
  • hypoglycemia- induced neurodegeneration neurodegeneration associated with epileptic seizure
  • neurodegeneration associated with neurotoxin poisoning and multi-system atrophy.
  • the neurodegenerative disorder or condition involves neurodegeneration of striatal medium spiny neurons in a mammal, including a human.
  • the neurodegenerative disorder or condition is Huntington's disease.
  • Stereoisomer 1 (tetrahydrofuran-3- yl)quinazolin-4-amine 1 100 300 1300
  • II III L is a leaving group, e.g. CI, Br, I, methanesulfonyl, 4-toluenesulfonyl.
  • This reaction is typically carried out in a solvent such as, for example, toluene, optionally in the presence of a carbonate base, at a temperature range of from about 0° C to about 200° C.
  • suitable solvents include benzene, chloroform, dioxane, ethyl acetate, 2-propanol and xylene.
  • solvent mixtures such as toluene/2-propanol can be used.
  • the reactants are heated under reflux in DMSO or DMF for a period of from about 2 hours to about 24 hours, optionally using a microwave oven.
  • the reaction depicted in Scheme 1 can also conveniently be carried out in a palladium-catalyzed fashion.
  • a mixture of a compound of formula II, a compound of formula III and a palladium (II) source such as Pd(OAc)2 or Pd2(dba)3 is heated in a convenient solvent such as toluene in the presence of a bisphosphine ligand, such as 2,2'-bis(diphenylphosphino)-1 ,1 '-binaphthyl "BINAP", and an alkoxide base such as sodium terf-butoxide.
  • the reaction mixture is stirred at 100°C for 7hr, followed by purification of the product by preparative HPLC to obtain the desired product.
  • This reaction is typically carried out in a suitable solvent, such as dimethyl- formannide, dimethylacetannide, tetrahydrofuran or acetonitrile, in the presence of a suitable base such as a carbonate base, e.g. potassium carbonate, or a tertiary amine base, e.g. triethylamine or diisopropylethylamine, or a strong base such as sodium hydride at a temperature ranging from about 0° C to about 100° C.
  • a suitable base such as a carbonate base, e.g. potassium carbonate, or a tertiary amine base, e.g. triethylamine or diisopropylethylamine, or a strong base such as sodium hydride at a temperature ranging from about 0° C to about 100° C.
  • Step 1 4-Chloro-8-fluoro-7-methoxyquinazoline: Step 1 : Commercial available (CAS 1180497-45-3) 2-amino-3-fluoro-4- methoxybenzoic acid (8 g, 43.21 mmol) and ammonium acetate (67 g, 864 mol) in trimethoxymethane (250 mL) were stirred at 100°C for 12 hrs. The mixture was filtered and washed with water (3x20 mL), the white solid was dried under vacuum to give 8-fluoro-7-methoxyquinazolin-4(3H)-one (8 g, 95%).
  • Step 2 To a mixture of 8-fluoro-7-methoxyquinazolin-4(3H)-one (4.0 g, 20.6 mmol) and diisopropylethylamine (11 g, 82 mmol) in toluene (100 mL) was added POCI3 (6.32g, 41 .2mmol) at 0°C. The reaction was stirred at 100°C for 12 hrs. The mixture was then cooled to 20°C and poured into ice-water (100 mL). The water phase was extracted with dichloromethane (3x 1 00 mL). The combined organic phases were washed with brine (3x 1 0 mL) and concentrated under vacuum. The residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give 4-chloro-8-fluoro-7-methoxyquinazoline 3 g (70%).
  • Example 1 Example 1 :
  • Step 1 A solution of 4-chloro-8-fluoro-7-methoxyquinazoline (440 mg, 2.06 mmol), tetrahydrofuran-3-amine (200 mg, 2.29 mmol) and diisopropylethylamine (600 mg, 4.58 mmol) in DMF (30 mL) was stirred at 100°C for 12 hrs. The solution was concentrated under vacuum, and the residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give 8-fluoro-7- methoxy-/V-(tetrahydrofuran-3-yl)quinazolin-4-amine 500 mg (83%) as a white solid.
  • Step 2 To a solution of 8-fluoro-7-methoxy-/V-(tetrahydrofuran-3-yl)quinazolin-4- amine (480 mg, 1 .83 mmol) in THF (20 mL) was added a 60% suspension of NaH in mineral oil (100 mg, 2.74 mmol) at 0°C, then it was stirred at 0°C for 30 min and then allowed to warm to room temperature. Methyl iodide (388 mg, 2.74 mmol) was added at 20°C and the reaction was stirred at 20°C for 12 hrs. The solution was quenched with sat. aq. NH CI (2 mL), then concentrated under vacuum.
  • Stereoisomer 1 (first eluting by SFC): 75 mg
  • Stereoisomer 1 (first eluting by SFC): 180 mg
  • Step 1 To the suspension of commercial available (CAS 33234-36-5) 2-chloro-3- methoxybenzoic acid (19.5 g, 104 mmol) in acetic acid (100 mL) and H 2 O (100 mL) at room temperature was added bromine (10.8 mL, 209 mmol) dropwise. The resulting mixture was heated at 60°C overnight. Then cooled to room temperature and extracted with dichloromethane (3x200 mL). The combined organic phases were washed with water (3x300 mL), dried over Na 2 SO 4 , filtered and concentrated to give 6-bromo-2-chloro-3-methoxybenzoic acid 23 g (83%).
  • Step 2 To as suspension of 6-bromo-2-chloro-3-methoxybenzoic acid (10 g, 38 mmol) in toluene (200 mL) was added diphenylphosphoryl azide (12.2 mL, 56.6 mmol) triethylamine (15.8 mL, 113 mmol) and tert-butanol (18.0 ml, 188 mmol). The reaction mixture was heated at 100°C for 2 hrs under N 2 . The mixture was evaporated and the residue was diluted with ethyl acetate. The organic phase was washed with 5% aqueous citric acid solution, water, sat. aq.
  • Step 4 To a solution of 6-bromo-2-chloro-3-nnethoxyaniline (8.3 g, 35 mmol) in methanol (300 mL) was added 1 ,3-bis(diphenylphosphino)propane (2.90 g, 7.02 mmol), Pd(AcO) 2 (1 .58 g, 7.02 mmol) and t ethylamine (4.89 mL, 35.1 mmol). The reaction mixture was stirred at 100°C under an atmosphere of CO (3 MPa) for 2 days. The mixture was cooled to room temperature and filtered. The filtrate was concentrated and the residue was dissolved in dichloromethane.
  • Step 6 To a solution of 2-amino-3-chloro-4-methoxybenzoic acid (700 mg, 3.47 mmol) in CH(OMe)3 (40 mL) was added ammonium acetate (5.35 g, 69.4 mmol). The mixture was then heated at 90°C overnight. The reaction was cooled to room temperature, filtered and the filter cake was collected, washed with water and dried to give 8-chloro-7-methoxyquinazolin-4(3H)-one 630 mg (86%).
  • Step 7 To an ice-cold solution of 8-chloro-7-methoxyquinazolin-4(3H)-one (630 mg, 2.99 mmol) in toluene (15 mL) was dropwise added POCI3 (0.56 mL, 6.0 mmol) and diisopropylethylamine (2.08 mL, 12.0 mmol). The mixture was heated at 100°C overnight, then cooled to room temperature and carefully poured into ice-water. The water phase was extracted with dichloromethane (2x30 mL). The combined organic phases were washed with water, dried over Na2SO 4 , filtered, concentrated in vacuo. The crude product was purified by flash chromatography on silica gel using a gradient of dichloromethane and ethyl acetate to give 4,8-dichloro-7- methoxyquinazoline 580 mg (85%).
  • the racemic mixture (650 mg) was purified by SFC (Column : Chiral Pak AD 5 ⁇ , Daicel Chemical Industries, Ltd, 250x30mm I.D.) separation and numbered according to the order of elution:
  • Stereoisomer 1 (first eluting by SFC): 200 mg
  • a mixture of stereoisomers (750 mg) was purified by SFC separation (column: Chiral Pak AD 5 ⁇ ,Daicel Chemical Industries, Ltd) and numbered according to the order of elution: Stereoisomer 1 (first eluting by SFC): 131 mg
  • the racemic mixture (200 mg) was purified by SFC (Column: Chiralpak AD
  • Cis-4-(8-fluoro-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole A mixture of 4-chloro-8-fluoro-7-methoxyquinazoline (320 mg, 1 .50 mmol), cis- hexahydro-2H-furo[3,2-b]pyrrole (200 mg, 1 .77 mmol) and diisopropylethylamine (457 mg, 3.54 mmol) in DMF (30 mL) was stirred at 100 °C for 12 hrs.
  • Step 1 To a suspension of 2-amino-3-bromo-4-methoxybenzoic acid (CAS1 180497- 47-5) (5.50 g, 22.4 mmol) in trimethoxymethane (100 mL) was added NH 4 OAc (17.2 g, 224 mmol). The mixture was heated at 90 °C for 12 hrs. The mixture was cooled to 25°C, the solid was filtered off, washed with H 2 O (50 mL) and dried in vacuo to give 8-bromo-7-methoxyquinazolin-4(3H)-one 3.50 g (61 .4%).
  • Step 2 To an ice-cold solution of 8-bromo-7-methoxyquinazolin-4(3H)-one (3.50 g, 13.7 mmol) in dry toluene (50 mL) was added diisopropylethylamine (7.09 g, 54.9 mmol) and POCI3 (18 g, 0.12 mol) dropwise. The mixture was heated at 100 °C for 12 hrs, then cooled to 25 °C and poured into H 2 O (100 mL). The aqueous layer was extracted with dichloromethane (100 mL). The organic layer was dried over Na 2 SO 4 , filtered and concentrated in vacuo.
  • stereoisomer 2 To an ice-cold solution of stereoisomer 1 of (example 7) 8-chloro-7-methoxy-/V-(3- methyltetrahydrofuran-3-yl)quinazolin-4-amine (200 mg, 0.681 mmol) in THF (10 mL) was added NaH (60% dispersion in mineral oil) (41 mg, 1 .0 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (126 mg, 0. 885 mmol) was added. The mixture was heated to 25 °C and stirred for 3 hrs.
  • Stereoisomer 2 300 mg (1 1 .9%)
  • stereoisomer 1 example 12 200 mg, 0.650 mmol
  • THF 10 mL
  • NaH 50% dispersion in mineral oil
  • Mel 120 mg, 0.845 mmol
  • the reaction was allowed to warm to 25 °C and stirred for 3 hrs.
  • H 2 O 5 mL was added to the mixture and the THF was removed in vacuo. The residue was extracted with dichloromethane (2x20 mL).
  • Stereoisomer 2 To an ice-cold solution of stereoisomer 2 example (200 mg, 0.650 mmol) in THF (10 ml_) was added NaH (60% dispersion in mineral oil) (39 mg, 0.98 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (120 mg, 0.845 mmol) was added. The reaction was stirred at 25 °C for 3 hrs and then H 2 O (5 ml_) was added. THF was removed in vacuo and the residue extracted with dichloromethane (2x20 ml_). The combined organic phases were washed with H 2 O (10 ml_), dried over Na 2 SO 4 , and concentrated in vacuo.
  • Stereoisomer 4 To an ice-cold solution of stereoisomer 4 example 1 2 (200 mg, 0.650 mmol) in THF (1 0 mL) was added NaH (60% dispersion in oil) (39 mg, 0.98 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (1 20 mg, 0.845 mmol) was added. The reaction was stirred at 25°C for 3 hrs. Then H 2 O (5 mL) was added and THF was removed in vacuo.
  • stereoisomer 1 of example 5 (8-chloro-7-methoxy-/V-(2- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (250 mg, 0.851 mmol) in THF (10 mL) was added a 60% suspension of NaH in mineral oil (61 mg, 1 .5 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (181 mg, 1 .28 mmol) was added at 0 °C. After stirring at 30 °C for 3 hrs H 2 O (5 mL) was added to the mixture. THF was removed in vacuo and the residue was extracted with dichloromethane (2x20 mL).
  • stereoisomer 2 of example 5 (8-chloro-7-methoxy-/V-(2- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (250 mg, 0.851 mmol) in THF (10 mL) was added a 60% suspension in mineral oil of NaH (61 mg, 1 .5 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (181 mg, 1 .28 mmol) was added. The reaction was stirred at 30 °C for 3 hrs before addition of H 2 O (5 mL). THF was removed in vacuo and the residue was extracted with dichloromethane (2x20 ml_).
  • stereoisomer 3 of example 5 (8-chloro-7-methoxy-/V-(2- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (160 mg, 0.545 mmol) in THF (10 ml_) was added a 60% suspension of NaH in mineral oil (39 mg, 0.98. mmol) and the mixture was stirred at 0 °C for 30 min. Mel (1 1 6 mg, 0.81 7 mmmol) was added at 0°C. The reaction was stirred at 30 °C for 3 hrs and then H 2 O (5 ml_) was added. THF was removed in vacuo and the residue was extracted with dichloromethane (2x20 ml_).
  • stereoisomer 4 of example 5 (8-chloro-7-methoxy-/V-(2- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (200 mg, 0.681 mmol) in THF (10 mL) was added a 60% suspension of NaH in mineral oil (49 mg, 1 .2 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (145 mg, 1 .02 mmol) was added. The reaction was stirred at 30 °C for 3 hrs and then H 2 O (5 mL) was added. THF was removed in vacuo and the residue was extracted with dichloromethane (2x20 mL).
  • Stereoisomer 1 To solution of stereoisomer 1 of example 1 (8-fluoro-7-methoxy-/V-(3- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (200 mg, 0.721 mmol) in THF (4 mL) was added a 60% suspension of NaH in mineral oil (43 mg, 1 .1 mmol) at 0 °C. After stirring for 30 min the reaction was heated to 20 °C. Mel (154 mg, 1 .08 mmol) was added and the reaction was stirred for 12 hrs. The reaction was quenched with sat. aq. NH CI (0.5 mL) and concentrated in vacuo.
  • stereoisomer 2 of example 1 (8-fluoro-7-methoxy-/V-(3- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (200 mg, 0.721 mmol) in THF (4 mL) was added a 60% suspension in mineral oil NaH (43 mg, 1 .1 mmol) at 0 °C and the reaction was stirred for 30 min before being heated at 20 °C. Mel (154 mg, 1 .08 mmol) was added and stirring continued for 12 hrs. The solution was quenched with sat. aq. NH CI (1 mL) and concentrated in vacuo.
  • Stereoisomer 1 To a solution of stereoisomer 2 of example 3 (A/-(2,3-dimethyltetrahydrofuran-3-yl)-8- fluoro-7-methoxyquinazolin-4-amine) (150 mg, 0.540 mmol) in dry THF (5 mL) was added a 60% suspension of NaH in mineral oil (32 mg, 0.81 mmol) at 0 °C under N 2 . The mixture was stirred at 0 °C for 30 min, then CH 3 I (92 mg, 0.65 mmol) was added. The reaction was stirred for 2 hrs at 0 °C before addition of sat. aq. NH CI (5 mL).
  • Stereoisomer 2 To a solution of stereoisomer 1 of example 3 (A/-(2,3-dimethyltetrahydrofuran-3-yl)-8- fluoro-7-methoxyquinazolin-4-amine) (150 mg, 0.540 mmol) in THF (5 mL) was added a 60% suspension of NaH in mineral oil (32 mg, 0.81 mmol) at 0 °C under N 2 .
  • stereoisomer 3 of example 3 (A/-(2,3-dimethyltetrahydrofuran-3-yl)- 8-fluoro-7-methoxyquinazolin-4-amine) (150 mg, 0.540 mmol) in THF (5 mL) was added a 60% suspension of NaH in mineral oil (32 mg, 0.81 mmol) at 0 °C under N 2 and the mixture was stirred for 30 min. Methyliodide (77 mg, 0.54 mmol) was added at 0 °C and stirring was continued for 2 hrs at 0 °C. The reaction was quenched by sat. aq.
  • stereoisomer 4 of example 3 (A/-(2,3-dimethyltetrahydrofuran-3-yl)-8- fluoro-7-methoxyquinazolin-4-amine) (150 mg, 0.541 mmol) in THF (5 ml_) was added a 60% suspension of NaH in mineral oil (32 mg, 0.81 mmol) at 0 °C under N 2 and the mixture was stirred for 30 min. Then methyliodide (92 mg, 0.65 mmol) stirring was continued for 2 hrs at 0 °C. The reaction was quenched by addition of sat. aq. NH CI (5 ml_).
  • Stereoisomer 2 To an ice-cold solution of stereoisomer 2 of example 17 (A/-(2,3- dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxyquinazolin-4-amine) (200 mg, 0.687 mmol) in THF (10 mL) was added a 60% suspension of NaH in mineral oil (55 mg,
  • stereoisomer 4 of example 17 (A/-(2,3- dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxyquinazolin-4-amine) (200 mg, 0.687 mmol) in THF (10 mL) was added a 60% suspension of NaH in mineral oil (55 mg,
  • stereoisomer 1 of example 17 (A/-(2,3- dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxyquinazolin-4-amine) (200 mg, 0.687 mmol) in THF (10 mL) was added a 60% suspension of NaH (55 mg, 1 .4 mmol). The reaction was stirred at 0 °C for 30 min and then methyliodide (146 mg, 1 .03 mmol) was added. The mixture was allowed to warm to 30 °C and stirred for 2 hrs. H 2 O (5 mL) was added to the mixture and THF was removed in vacuo.
  • PDE1A, PDE1 B and PDE1 C assays were performed as follows: the assays was performed in 60 ⁇ _ samples containing a fixed amount of the PDE1 enzyml (sufficient to convert 20-25% of the cyclic nucleotide substrate), a buffer (50 mM HEPES pH 7.6; 10 mM MgCI 2 ; 0.02% Tween20), 0.1 mg/ml BSA, 15 nM tritium labelled cAMP and varying amounts of inhibitors.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention provides halogenated quinazolin-THF-amines as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Description

Halogenated quinazolin-THF-amines as PDE1 inhibitors
FIELD OF THE INVENTION
The present invention provides compounds that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
BACKGROUND OF THE INVENTION
Throughout this application, various publications are referenced in full. The disclosures of these publications are hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.
The second messenger cyclic Nucleotides (cNs), cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) play a major role in intracellular signal transduction cascade, by regulating cN-dependent protein kinases (PKA and PKG), EPACs (Exchange Protein Activated by cAMP), phosphoprotein phosphatases, and/or cN-gated cation channels. In neurons, this includes the activation of cAMP- and cGMP-dependent kinases and subsequent phosphorylation of proteins involved in acute regulation of synaptic transmission as well as in neuronal differentiation and survival. Intracellular concentrations of cAMP and cGMP are strictly regulated by the rate of biosynthesis by cyclases and by the rate of degradation by phosphodiesterases (PDEs, EC 3.1 .4.17). PDEs are bimetallic hydrolases that inactivate cAMP/cGMP by catalytic hydrolysis of the 3'-ester bond, forming the inactive 5'-monophosphate. Since PDEs provide the only means of degrading the cyclic nucleotides cAMP and cGMP in cells, PDEs play an essential role in cyclic nucleotide signalling. The catalytic activities of PDEs provide for breakdown of cNs over a spectrum of concentrations in all cells, and their varied regulatory mechanisms provide for integration and crosstalk with myriad signalling pathways. Particular PDEs are targeted to discrete compartments within cells where they control cN level and sculpt microenvironments for a variety of cN signalosomes (Sharron H. Francis, Mitsi A. Blount, and Jackie D. Corbin. Physiol Rev 201 1 , 91 : 651-690).
On the basis of substrate specificity, the PDE families can be divided into three groups: 1 ) The cAMP-specific PDEs, which include PDE4, PDE7, and PDE8, 2) the cGMP-selective enzymes PDE5 and PDE9, and 3) the dual-substrate PDEs, PDE1 , PDE2, PDE3, as well as PDE10 and PDE1 1 .
Previously named calmodulin-stimulated PDE (CaM-PDE), PDE1 is unique in that it is Ca2+-dependently regulated via calmodulin (CaM, a 16 kDa Ca2+-binding protein) complexed with four Ca2+ (for review, Sharron H. Francis, Mitsi A. Blount, and Jackie D. Corbin. Physiol Rev 201 1 , 91 : 651-690). Thus, this family represents an interesting regulatory link between cyclic nucleotides and intracellular Ca2+. The PDE1 family is encoded by three genes: PDE1A (mapped on human chromosome 2q32), PDE1 B (human chromosome location, hcl: 12q13) and PDE1 C (hcl: 7p14.3). They have alternative promoters and give rise to a multitude of proteins by alternative splicing which differ in their regulatory properties, substrate affinities, specific activities, activation constants for CaM, tissue distribution and molecular weights. More than 10 human isoforms are identified. Their molecular weights vary from 58 to 86 kDa per monomer. The N-terminal regulatory domain that contains two Ca27CaM binding domains and two phosphorylation sites differentiate their corresponding proteins and modulate their biochemical functions. PDE1 is a dual substrate PDE and the PDE1 C-subtype has equal activity towards cAMP and cGMP (Km « 1 -3 μΜ), whereas the subtypes PDE1A and PDE1 B has a preference for cGMP (Km for cGMP * 1 -3 μΜ and for cAMP * 10-30 μΜ). The PDE1 subtypes are highly enriched in the brain and located especially in the striatum (PDE1 B), hippocampus (PDE1A) and cortex (PDE1A) and this localization is conserved across species (Amy Bernard et al. Neuron 2012, 73, 1083-1099). In the cortex, PDE1A is present mainly in deep cortical layers 5 and 6 (output layers), and used as a specificity marker for the deep cortical layers. PDE1 inhibitors enhance the levels of the second messenger cNs leading to enhanced neuronal excitability. Thus, PDE1 is a therapeutic target for regulation of intracellular signalling pathways, preferably in the nervous system and PDE1 inhibitors can enhance the levels of the second messengers cAMP/cGMP leading to modulation of neuronal processes and to the expression of neuronal plasticity-related genes, neurotrophic factors, and neuroprotective molecules. These neuronal plasticity enhancement properties together with the modulation of synaptic transmission make PDE1 inhibitors good candidates as therapeutic agents in many neurological and psychiatric conditions. The evaluation of PDE1 inhibitors in animal models (for reviews see e.g. Blokland et al. Expert Opinion on Therapeutic Patents (2012), 22(4), 349-354; and Medina, A. E. Frontiers in Neuropharmacology (201 1 ), 5(Feb.), 21 ) have suggested the potential for the therapeutic use of PDE1 inhibitors in neurological disorders, like e.g. Alzheimer's, Parkinson's and Huntington's Diseases and in psychiatric disorders like e.g. Attention Deficit Hyperactivity Disorder (ADHD), restless leg syndrome, depression, narcolepsy, cognitive impairment and cognitive impairment associated with schizophrenia (CIAS). There have also been patent applications claiming that PDE1 inhibitors are useful in diseases that may be alleviated by the enhancement of progesterone-signalling such as female sexual dysfunction e.g. WO-2010065153.
SUMMARY OF THE INVENTION PDE1 enzymes are expressed in the Central Nervous System (CNS), making this gene family an attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders.
The compounds of the invention may offer alternatives to current marketed treatments for neurodegenerative and/or psychiatric disorders, which are not efficacious in all patients. Hence, there remains a need for alternative methods of treatment.
The objective of the present invention is to provide compounds that are PDE1 inhibitors, and as such are useful to treat neurodegenerative disorders and psychiatric disorders. In a preferred embodiment the compounds are selective PDE1 inhibitors. Accordingly, the present invention relates to compounds of formula (I)
(I) wherein X is halogen, preferably fluorine or chlorine or bromine;
Ri is selected from the group consisting of H and Ci- C3 alkyi, wherein the alkyi optionally may be substituted one, two or three times with fluorine;
R2 is selected from the group consisting of H and Ci-C4 alkyi, wherein the Ci-C4 alkyi optionally is substituted one or more times with one or more substituents, R3 is selected from the group consisting of H and C1-C6 alkyi, wherein the C1-C6 alkyi optionally is substituted one or more times with one or more substituents,
R and R5 independently of each other are selected from the group consisting of H, C1-C6 alkyi, optionally is substituted one or more times with one or more substituents, C3-C6 cycloalkyl, fluorine, chlorine, hydroxy and alkoxy, R6 and R7 independently of each other are selected from the group consisting of H and C1-C6 alkyi, wherein the C1-C6 alkyi optionally is substituted one or more times with one or more substituents, Rs and Rg independently of each other are selected from the group consisting of H and C1-C6 alkyl, wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents, and pharmaceutically acceptable acid addition salts of Compound I, racemic mixtures of Compound I, or the corresponding enantiomer and/or diastereo-isomer of Compound I, and polymorphic forms of Compound I as well as tautomeric forms of Compound I.
DETAILED DESCRIPTION OF THE INVENTION EMBODIMENTS OF THE INVENTION
In a first embodiment (E1 ) the present invention relates to compounds of formula (I) (Compound I)
Compound (I) wherein
Ri is selected from the group consisting of H and C1-C3 alkyl, wherein the alkyl optionally may be substituted one, two or three times with fluorine; R2 is selected from the group consisting of H and Ci-C4 alkyl wherein R2, when R2 is a Ci-C4 alkyl, may form a saturated five membered aliphatic ring with R9 wherein the Ci-C4 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of phenyl, monocyclic 5- or 6-membered heteroaryl, C3-C6 cycloalkyi, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl;
R3 is selected from the group consisting of H and C1-C6 alkyl wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of phenyl, monocyclic 5- or 6-membered heteroaryl, C3-C6 cycloalkyi, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl; R and R5 independently of each other are selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyi, fluorine, chlorine, hydroxy and alkoxy of the form -OR10 wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of phenyl, monocyclic 5- or 6-membered heteroaryl, C3-C6 cycloalkyi, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl;
R6 and R7 independently of each other are selected from the group consisting of H and C1-C6 alkyl wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of C3-C6 cycloalkyi, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl; Rs and Rg independently of each other are selected from the group consisting of H and C1-C6 alkyl wherein R9, when R9 is a C1-C6 alkyl, may form a saturated aliphatic five membered ring with R2 wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of C3-C6 cycloalkyl, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl; and/or pharmaceutically acceptable acid addition salts of Compound I, racemic mixtures of Compound I, or the corresponding enantiomer and/or optical isomer of Compound I, and polymorphic forms of Compound I as well as tautomeric forms of Compound I.
In an embodiment (E2) of (E1 ) R2 is H or -CH3.
In an embodiment (E3) of any of (E1 ) and (E2) at least one of R6 and R7 is H. In an embodiment (E4) of (E3) both R6 and R7 are H.
In an embodiment (E5) of (E1 ) at least four of R3 to Rg are H.
In an embodiment (E6) of (E1 ) when any of R3, R4 or R5 are alkyl, then at most one of them is substituted at most once with phenyl or monocyclic 5- or 6-membered heteroaryl. In an embodiment (E7) of (E1 ) R2 and Rg form a five-membered saturated aliphatic ringsystem.
In an embodiment (E8) of (E1 ) Ri is substituted one time with fluorine. In an embodiment (E9) of (E1 ) Ri is substituted two times with fluorine. In an embodiment (E10) of (E1 ) Ri is substituted three times with fluorine. In an embodiment (E1 1 ) of (E1 ) X is fluorine. In an embodiment (E12) of (E1 ) X is chlorine.
In an embodiment (E13) of any of (E1 ) to (E12) the compound is selected from the group of compounds listed in Table 1 .
In an embodiment (E14) of any of (E1 ) to (E13) the compound is a PDE1A inhibitor. In an embodiment (E15) of any of (E1 ) to (E13) the compound is a PDE1 B inhibitor.
In an embodiment (E16) of any of (E1 ) to (E13) the compound is a PDE1 C inhibitor.
In an embodiment (E17) the compound of any of (E1 ) to (E16) is for use as a medicament.
In an embodiment (E18) the compound of any of (E1 ) to (E16) is use in the treatment of attention-deficit hyperactivity disorder (ADHD)
Embodiment (E19): A pharmaceutical composition comprising the compound of any of (E1 ) to (E16) and one or more pharmaceutically acceptable carriers.
Embodiment (E20): A pharmaceutical composition according to (E19) for use in a method of treatment of attention-deficit/hyperactivity disorder (ADHD) Embodiment (E21 ): A compound of any one of (E1 ) to (E16) for use in a method for the treatment of attention-deficit/hyperactivity disorder (ADHD)
Embodiment (E22): A compound of any one of (E1 ) to (E16) for the preparation of a medicament for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). Embodiment (E23): A method of treating a subject suffering of attention- deficit/hyperactivity disorder (ADHD) which method comprises administering an effective amount of a compound of any one (E1 ) to (E16).
Embodiment (E24): A pharmaceutical composition according to (E19) for use in a method of treatment of neurodegenerative disorder. Embodiment (E25): A compound of any one of (E1 ) to (E16) for use in a method for the treatment of neurodegenerative disorder. Embodiment (E26): A compound of any one of (E1 ) to (E16) for the preparation of a medicament for use in the treatment of neurodegenerative disorder.
Embodiment (E27): A method of treating a subject suffering of a neurodegenerative disorder which method comprises administering an effective amount of a compound of any one (E1 ) to (E16).
In an embodiment (E28) of any of embodiments (E24) to (E27) the neurodegenerative disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease and Huntington's Disease or for the treatment of a psychiatric disorder such as Attention Deficit hyperactivity Disorder (ADHD), depression, narcolepsy, cognitive impairment and cognitive impairment associated with schizophrenia (CIAS).
Embodiment (E29): Use of a compound of any of claims 1 -7 in the manufacture of a medicament for the treatment of a neurodegenerative disorder, such as Alzheimer's Disease, Parkinson's Disease and Huntington's Disease or for the treatment of a psychiatric disorder such as Attention Deficit hyperactivity Disorder (ADHD), depression, narcolepsy, cognitive impairment and cognitive impairment associated with schizophrenia (CIAS) or a brain disease like restless leg syndrome.
Embodiment (E30): In an embodiment (E30) of (E1 ) Ri is H.
DEFINITIONS
PDE1 ENZYMES
The PDE1 isozyme family includes numerous splice variant PDE1 isoforms. It has three subtypes, PDE1A, PDE1 B and PDE1 C which divide further into various isoforms. In the context of the present invention PDE1 and PDE1 enzymes are synonymous and refer to PDE1A, PDE1 B and PDE1 C enzymes as well as their isoforms.
SUBSTITUENTS As used in the context of the present invention, the terms "halo" and "halogen" are used interchangeably and refer to fluorine, chlorine, bromine or iodine.
The terms "C1-C3 alkyl", "Ci-C4 alkyl", "C1-C5 alkyl" and "Ci-C6 alkyl" refer to a straight-chain or branched saturated hydrocarbon having from one to six carbon atoms, inclusive. Examples of such groups include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1 -butyl, and n- hexyl.
The term "C3-C6 cycloalkyl" refers to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The expression "alkoxy" refers to a straight-chain or branched saturated alkoxy group having from one to six carbon atoms, inclusive, with the open valency on the oxygen. Examples of such groups include, but are not limited to, methoxy, ethoxy, n- butoxy, 2-methyl-pentoxy and n-hexyloxy.
The term "aryl" refers to a phenyl ring, optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy or halo(Ci-Ce)alkyl as defined above.
The term "heteroaryl" refers to monocyclic- or polycyclic aromatic ring comprising carbon atoms, hydrogen atoms, and one or more heteroatoms, preferably, 1 to 3 heteroatoms, independently selected from nitrogen, oxygen, and sulfur. Illustrative examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1 ,2,3,)- and (1 ,2,4)-triazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, furanyl, thiophenyl, isoxazolyl, thiazolyl, isoxazolyl, and oxazolyl. A heteroaryl group can be unsubstituted or substituted with one or two suitable substituents. Preferably, the heteroaryl of this invention is a monocyclic 5 or 6 membered heteroaryl, wherein the ring comprises 2 to 5 carbon atoms and 1 to 3 heteroatoms, referred to herein as "monocyclic 5 or 6 membered heteroaryl".
ISOMERIC FORMS
Where compounds of the present invention contain one or more chiral centers reference to any of the compounds will, unless otherwise specified, cover any of the enantiomerically or diastereomerically pure compounds as well as mixtures of the enantiomers or diastereomers in any ratio.
For example reference to the compound 8-fluoro-7-methoxy-/V-(3- methyltetrahydrofuran-3-yl)quinazolin-4-amine without any further specification covers (R)- 8-fluoro-7-methoxy-/V-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine, (S)- 8-fluoro-7-methoxy-/V-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine as well as mixtures of the enantiomers in any ratio, including the racemic mixture (±)8-fluoro- 7-methoxy-/V-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine.
Correspondingly, reference to the compound 8-fluoro-7-methoxy-/V-(2- methyltetrahydrofuran-3-yl)quinazolin-4-amine without any further specification covers all four stereoisomeric variants as well as mixtures thereof in any ratio, including the racemic mixtures.
The above also applies where compounds of the invention contain more than two chiral centers.
PDE1 INHIBITORS
In the context of the present invention a compound is considered to be a PDE1 inhibitor if the amount required to reach the IC5o level of PDE1 B is 5 micro molar or less, preferably less than 4 micro molar, such as 3 micro molar or less, more preferably 2 micro molar or less, such as 1 micro molar or less, in particular 500 nM or less. In preferred embodiments the required amount of PDE1 inhibitor required to to reach the IC5o level of PDE1 B is 400nM or less, such as 300 nM or less, 200nM or less, 100 nM or less, or even 80 nM or less, such as 50 nM or less, for example 25 nM or less. PHARMACEUTICALLY ACCEPTABLE SALTS
The present invention also comprises pharmaceutically acceptable salts of the compounds. Such salts include acid addition salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p- toluenesulfonic acids, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Berge, S.M. et al., J. Pharm. Sci. 1977, 66, 2, the contents of which are hereby incorporated by reference.
Furthermore, the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
THERAPEUTICALLY EFFECTIVE AMOUNT
In the present context, the term "therapeutically effective amount" of a compound means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and/or its complications in a therapeutic intervention comprising the administration of said compound. An amount adequate to accomplish this is defined as "therapeutically effective amount". Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician.
In the present context, the term "treatment" and "treating" means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder. The term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to relief the symptoms and complications, and/or to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications. Nonetheless, prophylactic (preventive) and therapeutic (curative) treatments are two separate aspects of the invention. The patient to be treated is preferably a mammal, in particular a human being.
PHARMACEUTICAL COMPOSITIONS
The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier or diluent. The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of one of the specific compounds disclosed in the Experimental Section herein and a pharmaceutically acceptable carrier or diluent.
The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers, diluents or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 21 th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 2005. The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) routes. It will be appreciated that the route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient.
Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, the compositions may be prepared with coatings such as enteric coatings or they may be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art. Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs. Pharmaceutical compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Other suitable administration forms include, but are not limited to, suppositories, sprays, ointments, creams, gels, inhalants, dermal patches and implants.
Typical oral dosages range from about 0.001 to about 100 mg/kg body weight per day. Typical oral dosages also range from about 0.01 to about 50 mg/kg body weight per day. Typical oral dosages further range from about 0.05 to about 10 mg/kg body weight per day. Oral dosages are usually administered in one or more dosages, typically, one to three dosages per day. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art. The formulations may also be presented in a unit dosage form by methods known to those skilled in the art. For illustrative purposes, a typical unit dosage form for oral administration may contain from about 0.01 to about 1000 mg, from about 0.05 to about 500 mg, or from about 0.5 mg to about 200 mg.
For parenteral routes such as intravenous, intrathecal, intramuscular and similar administration, typical doses are in the order of half the dose employed for oral administration.
The present invention also provides a process for making a pharmaceutical composition comprising mixing a therapeutically effective amount of a compound of formula (I) and at least one pharmaceutically acceptable carrier or diluent. In an embodiment, of the present invention, the compound utilized in the aforementioned process is one of the specific compounds disclosed in the Experimental Section herein.
The compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof. One example is an acid addition salt of a compound having the utility of a free base. When a compound of formula (I) contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of formula (I) with a molar equivalent of a pharmaceutically acceptable acid. Representative examples of suitable organic and inorganic acids are described above.
For parenteral administration, solutions of the compounds of formula (I) in sterile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The compounds of formula (I) may be readily incorporated into known sterile aqueous media using standard techniques known to those skilled in the art.
Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. Examples of solid carriers include lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose. Examples of liquid carriers include, but are not limited to, syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The pharmaceutical compositions formed by combining the compounds of formula (I) and a pharmaceutically acceptable carrier are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy. Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and optionally a suitable excipient. Furthermore, the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in- water or water-in-oil liquid emulsion.
If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it may be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will range from about 25 mg to about 1 g per dosage unit. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
The pharmaceutical compositions of the invention may be prepared by conventional methods in the art. For example, tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tableting machine prepare tablets. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatin, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colorings, flavorings, preservatives etc. may be used provided that they are compatible with the active ingredients. TREATMENT OF DISORDERS
As mentioned above, the compounds of formula (I) are PDE1 enzyme inhibitors and as such are useful to treat associated neurological and psychiatric disorders.
The invention thus provides a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof, as well as a pharmaceutical composition containing such a compound, for use in the treatment of a neurodegenerative disorder, psychiatric disorder or drug addiction in mammals including humans; wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit/hyperactivity disorder; and age- related cognitive decline; and wherein the psychiatric disorder is selected from the group consisting of schizophrenia, for example of the paranoid, disorganized, catatonic, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the depressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type; and wherein the drug addiction is an alcohol, amphetamine, cocaine, or opiate addiction.
The compounds of formula (I) or pharmaceutically acceptable salts thereof may be used as the sole active ingredient or in combination with one or more other drugs in the treatment of diseases or conditions for which the compounds of the present invention have utility, where the combination of the drugs together are safer or more effective than either drug alone. Additionally, the compounds of the present invention may be used in combination with one or more other drugs that treat, prevent, control, ameliorate, or reduce the risk of side effects or toxicity of the compounds of the present invention. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with the compounds of the present invention. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to the compounds of the present invention. The combinations may be administered as part of a unit dosage form combination product, or as a kit or treatment protocol wherein one or more additional drugs are administered in separate dosage forms as part of a treatment regimen.
The present invention provides a method of treating a mammal, including a human, suffering from a neurodegenerative disorder selected from a cognition disorder or movement disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I).
This invention further provides a method of treating a neurodegenerative disorder or condition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula (I) effective in inhibiting PDE1 . This invention also provides a method of treating a subject suffering from a psychiatric disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of psychiatric disorders that can be treated according to the present invention include, but are not limited to, Attention Deficit Hyperactivity Disorder (ADHD) schizophrenia, for example of the paranoid, disorganized, catatonic, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the depressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type; and the anxiety disorder is selected from panic disorder; agoraphobia; a specific phobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; acute stress disorder; and generalized anxiety disorder.
It has been found that the compounds of formula (I) or pharmaceutically acceptable salts thereof may advantageously be administered in combination with at least one neuroleptic agent (which may be a typical or an atypical antipsychotic agent) to provide improved treatment of psychiatric disorders such as schizophrenia. The combinations, uses and methods of treatment of the invention may also provide advantages in treatment of patients who fail to respond adequately or who are resistant to other known treatments. The present invention thus provides a method of treating a mammal suffering from a psychiatric disorder, such as schizophrenia, which method comprises administering to the mammal a therapeutically effective amount of a compound of formula (I), either alone or as combination therapy together with at least one neuroleptic agent.
The term "neuroleptic agent" as used herein refers to drugs, which have the effect on cognition and behaviour of antipsychotic agent drugs that reduce confusion, delusions, hallucinations, and psychomotor agitation in patients with psychoses. Also known as major tranquilizers and antipsychotic drugs, neuroleptic agents include, but are not limited to: typical antipsychotic drugs, including phenothiazines, further divided into the aliphatics, piperidines, and piperazines, thioxanthenes (e.g., cisordinol), butyrophenones (e.g., haloperidol), dibenzoxazepines (e.g., loxapine), dihydroindolones (e.g., molindone), diphenylbutylpiperidines (e.g., pimozide), and atypical antipsychotic drugs, including benzisoxazoles (e.g., risperidone), sertindole, olanzapine, quetiapine, osanetant and ziprasidone.
Particularly preferred neuroleptic agents for use in the invention are sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.
The present invention further provides a method of treating a subject suffering from a cognition disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of cognition disorders that can be treated according to the present invention include, but are not limited to, Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit hyperactivity disorder; and age-related cognitive decline.
This invention also provides a method of treating a movement disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of movement disorders that can be treated according to the present invention include, but are not limited to, Huntington's disease and dyskinesia associated with dopamine agonist therapy. This invention further provides a method of treating a movement disorder selected from Parkinson's disease and restless leg syndrome, which comprises administering to the subject a therapeutically effective amount of a compound of formula (I).
This invention also provides a method of treating a mood disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of mood disorders and mood episodes that can be treated according to the present invention include, but are not limited to, major depressive episode of the mild, moderate or severe type, a manic or mixed mood episode, a hypomanic mood episode; a depressive episode with a typical features; a depressive episode with melancholic features; a depressive episode with catatonic features; a mood episode with postpartum onset; post-stroke depression; major depressive disorder; dysthymic disorder; minor depressive disorder; premenstrual dysphoric disorder; post-psychotic depressive disorder of schizophrenia; a major depressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia; a bipolar disorder, for example bipolar I disorder, bipolar II disorder, and cyclothymic disorder. It is understood that a mood disorder is a psychiatric disorder. This invention further provides a method of treating a disorder comprising as a symptom a deficiency in attention and/or cognition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula (I) effective in treating said disorder.
Other disorders that can be treated according to the present invention are obsessive/compulsive disorders, Tourette's syndrome and other tic disorders. As used herein, and unless otherwise indicated, a "neurodegenerative disorder or condition" refers to a disorder or condition that is caused by the dysfunction and/or death of neurons in the central nervous system. The treatment of these disorders and conditions can be facilitated by administration of an agent which prevents the dysfunction or death of neurons at risk in these disorders or conditions and/or enhances the function of damaged or healthy neurons in such a way as to compensate for the loss of function caused by the dysfunction or death of at-risk neurons. The term "neurotrophic agent" as used herein refers to a substance or agent that has some or all of these properties. Examples of neurodegenerative disorders and conditions that can be treated according to the present invention include, but are not limited to, Parkinson's disease; Huntington's disease; dementia, for example Alzheimer's disease, multi- infarct dementia, AIDS-related dementia, and Fronto temperal Dementia; neurodegeneration associated with cerebral trauma; neurodegeneration associated with stroke, neurodegeneration associated with cerebral infarct; hypoglycemia- induced neurodegeneration; neurodegeneration associated with epileptic seizure; neurodegeneration associated with neurotoxin poisoning; and multi-system atrophy.
In one embodiment of the present invention, the neurodegenerative disorder or condition involves neurodegeneration of striatal medium spiny neurons in a mammal, including a human.
In a further embodiment of the present invention, the neurodegenerative disorder or condition is Huntington's disease.
All references, including publications, patent applications and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety (to the maximum extent permitted by law).
Headings and sub-headings are used herein for convenience only, and should not be construed as limiting the invention in any way.
The use of any and all examples, or exemplary language (including "for instance", "for example", "e.g.", and "as such") in the present specification is intended merely to better illuminate the invention, and does not pose a limitation on the scope of invention unless otherwise indicated.
The citation and incorporation of patent documents herein is done for convenience only, and does not reflect any view of the validity, patentability and/or enforceability of such patent documents.
The present invention includes all modifications and equivalents of the matter recited in the claims appended hereto, as permitted by applicable law.
COMPOUNDS OF THE INVENTION
PDE1 B PDE1 C
Compound PDE1A
Compound name IC50 IC50 number IC50 (nM)
(nM) (nM)
8-fluoro-7-methoxy-/V-(3-
1
methyltetrahydrofuran-3-
Stereoisomer 1
yl)quinazolin-4-amine 50 9.9 28
8-fluoro-7-methoxy-/V-(3-
1
methyltetrahydrofuran-3-
Stereoisomer 2
yl)quinazolin-4-amine 250 65 260
8-fluoro-7-methoxy-/V-
2 methyl-/V-
Stereoisomer 1 (tetrahydrofuran-3- yl)quinazolin-4-amine 1 100 300 1300
8-fluoro-7-methoxy-/V-
2 methyl-/V-
Stereoisomer 2 (tetrahydrofuran-3- yl)quinazolin-4-amine 100 18 76
8-fluoro-7-methoxy-/V-(2-
3
methyltetrahydrofuran-3-
Stereoisomer 1
yl)quinazolin-4-amine 1900 650 1800 PDE1 B PDE1 C
Compound PDE1A
Compound name IC50 IC50 number IC50 (nM)
(nM) (nM)
8-fluoro-7-methoxy-/V-(2-
3
methyltetrahydrofuran-3-
Stereoisomer 2
yl)quinazolin-4-amine 420 87 260
8-fluoro-7-methoxy-/V-(2-
3
methyltetrahydrofuran-3-
Stereoisomer 3
yl)quinazolin-4-amine 530 70 310
8-fluoro-7-methoxy-/V-(2-
3
methyltetrahydrofuran-3-
Stereoisomer 4
yl)quinazolin-4-amine 600 120 410
8-chloro-7-methoxy-/V-
4
(tetrahydrofuran-3-
Stereoisomer 1
yl)quinazolin-4-amine 790 310 200
8-chloro-7-methoxy-/V-
4
(tetrahydrofuran-3-
Stereoisomer 2
yl)quinazolin-4-amine 190 45 33
8-chloro-7-methoxy-/V-(2-
5
methyltetrahydrofuran-3- stereoisomer 1
yl)quinazolin-4-amine 300 49 27
8-chloro-7-methoxy-/V-(2-
5
methyltetrahydrofuran-3- stereoisomer 2
yl)quinazolin-4-amine 230 37 35
8-chloro-7-methoxy-/V-(2-
5
methyltetrahydrofuran-3- stereoisomer 3
yl)quinazolin-4-amine 1500 460 250
8-chloro-7-methoxy-/V-(2-
5
methyltetrahydrofuran-3- stereoisomer 4
yl)quinazolin-4-amine 450 58 36 PDE1 B PDE1 C
Compound PDE1A
Compound name IC50 IC50 number IC50 (nM)
(nM) (nM)
8-chloro-7-methoxy-/V-
6 methyl-/V- stereoisomer 1 (tetrahydrofuran-3- yl)quinazolin-4-amine 1800 330 140
8-chloro-7-methoxy-/V-
6 methyl-/V- stereoisomer 2 (tetrahydrofuran-3- yl)quinazolin-4-amine 150 15 1 1
8-chloro-7-methoxy-/V-(3-
7
methyltetrahydrofuran-3- stereoisomer 2
yl)quinazolin-4-amine 490 75 48
8-chloro-7-methoxy-/V-(3-
7
methyltetrahydrofuran-3- stereoisomer 1
yl)quinazolin-4-amine 200 23 1 1
8 cis-4-(8-fluoro-7- 72 21 60
Stereoisomer 1 methoxyquinazolin-4- yl)hexahydro-2H-furo[3,2- b]pyrrole
8 Stereoisomer 2 cis-4-(8-fluoro-7- 4034 2200 2500 methoxyquinazolin-4- yl)hexahydro-2H-furo[3,2- b]pyrrole
9 Stereoisomer 1 cis-4-(8-chloro-7- 156 40 23 methoxyquinazolin-4- yl)hexahydro-2H-furo[3,2- b]pyrrole
9 Stereoisomer 2 cis-4-(8-chloro-7- 2260 1200 550 methoxyquinazolin-4- yl)hexahydro-2H-furo[3,2- PDE1 B PDE1 C
Compound PDE1A
Compound name IC50 IC50 number IC50 (nM)
(nM) (nM) b]pyrrole
10 Stereoisomer cis-4-(8-bromo-7- 147 49 1 1 1 methoxyquinazolin-4- yl)hexahydro-2H-furo[3,2- b]pyrrole
10 Stereoisomer cis-4-(8-bromo-7- 10% 47% 210 2 methoxyquinazolin-4- yl)hexahydro-2H-furo[3,2- b]pyrrole
1 1 Stereoisomer 8-chloro-7-methoxy-/V- 292 65 33 1 methyl-/V-(3- methyltetrahydrofuran-3- yl)quinazolin-4-amine
1 1 Stereoisomer 8-chloro-7-methoxy-/V- 152 31 15 2 methyl-/V-(3- methyltetrahydrofuran-3- yl)quinazolin-4-amine
12 Stereoisomer 8-chloro-A/-(2,3- 853 200 130 1 dimethyltetrahydrofuran-
3-yl)-7- methoxyquinazolin-4- amine
12 Stereoisomer 8-chloro-A/-(2,3- 286 65 38 2 dimethyltetrahydrofuran-
3-yl)-7- methoxyquinazolin-4- amine
12 Stereoisomer 8-chloro-A/-(2,3- 145 21 14 3 dimethyltetrahydrofuran- PDE1 B PDE1 C
Compound PDE1A
Compound name IC50 IC50 number IC50 (nM)
(nM) (nM)
3-yl)-7- methoxyquinazolin-4- amine
12 Stereoisomer 8-chloro-/V-(2,3- 76 7 4 4 dimethyltetrahydrofuran-
3-yl)-7- methoxyquinazolin-4- amine
13 Stereoisomer 8-chloro-A/-(2,3- 2550 410 200 1 dimethyltetrahydrofuran- 3-yl)-7-methoxy-/V- methylquinazolin-4-amine
13 Stereoisomer 8-chloro-A/-(2,3- 207 34 17 2 dimethyltetrahydrofuran- 3-yl)-7-methoxy-/V- methylquinazolin-4-amine
13 Stereoisomer 8-chloro-A/-(2,3- 85 7 5 3 dimethyltetrahydrofuran- 3-yl)-7-methoxy-/V- methylquinazolin-4-amine
13 Stereoisomer 8-chloro-A/-(2,3- 300 26 13 4 dimethyltetrahydrofuran- 3-yl)-7-methoxy-/V- methylquinazolin-4-amine
14 Stereoisomer 8-chloro-7-methoxy-/V- 2642 510 200 1 methyl-/V-(2- methyltetrahydrofuran-3- yl)quinazolin-4-amine
14 Stereoisomer 8-chloro-7-methoxy-/V- 170 18 10 PDE1 B PDE1 C
Compound PDE1A
Compound name IC50 IC50 number IC50 (nM)
(nM) (nM)
2 methyl -N-(2- methyltetrahydrofuran-3- yl)quinazolin-4-amine
14 Stereoisomer 8-chloro-7-methoxy-/V- 1532 490 200 3 methyl-/V-(2- methyltetrahydrofuran-3- yl)quinazolin-4-amine
14 Stereoisomer 8-chloro-7-methoxy-/V- 285 30 14 4 methyl-/V-(2- methyltetrahydrofuran-3- yl)quinazolin-4-amine
15 Stereoisomer 8-fluoro-7-methoxy-/V- 688 1 10 320 1 methyl-/V-(3- methyltetrahydrofuran-3- yl)quinazolin-4-amine
15 Stereoisomer 8-fluoro-7-methoxy-/V- 333 47 81 2 methyl-/V-(3- methyltetrahydrofuran-3- yl)quinazolin-4-amine
16 Stereoisomer 8-fluoro-7-methoxy-/V- 1 180 430 1200 1 (tetrahydrofuran-3- yl)quinazolin-4-amine
16 Stereoisomer 8-fluoro-7-methoxy-/V- 315 81 230 2 (tetrahydrofuran-3- yl)quinazolin-4-amine
17 Stereoisomer N-{2,3- 451 100 390 3 dimethyltetrahydrofuran-
3-yl)-8-fluoro-7- methoxyquinazolin-4- PDE1 B PDE1 C
Compound PDE1A
Compound name IC50 IC50 number IC50 (nM)
(nM) (nM) amine
17 Stereoisomer N-{2,3- 73 5 22 2 dimethyltetrahydrofuran- 3-yl)-8-fluoro-7- methoxyquinazolin-4- amine
17 Stereoisomer N-{2,3- 408 140 440 4 dimethyltetrahydrofuran- 3-yl)-8-fluoro-7- methoxyquinazolin-4- amine
17 Stereoisomer N-{2,3- 184 27 98 1 dimethyltetrahydrofuran- 3-yl)-8-fluoro-7- methoxyquinazolin-4- amine
18 Stereoisomer 8-fluoro-7-methoxy-/V- 2467 550 1400 2 methyl-/V-(2- methyltetrahydrofuran-3- yl)quinazolin-4-amine
18 Stereoisomer 8-fluoro-7-methoxy-/V- 1732 510 1 100 1 methyl-/V-(2- methyltetrahydrofuran-3- yl)quinazolin-4-amine
18 Stereoisomer 8-fluoro-7-methoxy-/V- 200 47 87 3 methyl-/V-(2- methyltetrahydrofuran-3- yl)quinazolin-4-amine
18 Stereoisomer 8-fluoro-7-methoxy-/V- 515 60 120 PDE1 B PDE1 C
Compound PDE1A
Compound name IC50 IC50 number IC50 (nM)
(nM) (nM)
4 methyl -N-(2- methyltetrahydrofuran-3- yl)quinazolin-4-amine
19 Stereoisomer N-{2,3- 229 32 86 1 dimethyltetrahydrofuran- 3-yl)-8-fluoro-7-methoxy- /V-methylquinazolin-4- amine
19 Stereoisomer N-{2,3- 185 32 55 2 dimethyltetrahydrofuran- 3-yl)-8-fluoro-7-methoxy- /V-methylquinazolin-4- amine
19 Stereoisomer N-{2,3- 2487 420 1200 3 dimethyltetrahydrofuran- 3-yl)-8-fluoro-7-methoxy- /V-methylquinazolin-4- amine
19 Stereoisomer N-{2,3- 97 10 34 4 dimethyltetrahydrofuran- 3-yl)-8-fluoro-7-methoxy- /V-methylquinazolin-4- amine
Table 1 : Compounds of the invention EXPERIMENTAL SECTION
PREPARATION OF THE COMPOUNDS OF THE INVENTION
Compounds of the general formula I of the invention may be prepared as described in the following reaction schemes. Unless otherwise indicated, in the reaction schemes and discussion that follow, R1-R10, and X are as defined above. Scheme 1 below depicts a coupling reaction between a compound of formula II and a derivative of 3-amino tetrahydrofurane of formula III, to generate the substituted halogenated quinazolin-THF-amine compounds of formula I.
Scheme 1
II III L is a leaving group, e.g. CI, Br, I, methanesulfonyl, 4-toluenesulfonyl. This reaction is typically carried out in a solvent such as, for example, toluene, optionally in the presence of a carbonate base, at a temperature range of from about 0° C to about 200° C. Other suitable solvents include benzene, chloroform, dioxane, ethyl acetate, 2-propanol and xylene. Alternatively, solvent mixtures such as toluene/2-propanol can be used. Preferably the reactants are heated under reflux in DMSO or DMF for a period of from about 2 hours to about 24 hours, optionally using a microwave oven.
The reaction depicted in Scheme 1 can also conveniently be carried out in a palladium-catalyzed fashion. Typically, a mixture of a compound of formula II, a compound of formula III and a palladium (II) source such as Pd(OAc)2 or Pd2(dba)3 is heated in a convenient solvent such as toluene in the presence of a bisphosphine ligand, such as 2,2'-bis(diphenylphosphino)-1 ,1 '-binaphthyl "BINAP", and an alkoxide base such as sodium terf-butoxide. The reaction mixture is stirred at 100°C for 7hr, followed by purification of the product by preparative HPLC to obtain the desired product.
Starting materials of formula II i.e. quinazolines are either commercially available or can be prepared as described in the literature e.g. Dechantsreiter, Michael A. et al From PCT Int. Appl., 2013192345, 27 Dec 2013, Armarego, Wilfred L. F. and Reece, Phillip A. Australian Journal of Chemistry, 34(7), 1561 -6; 1981 , or as described in this patent application.
Starting materials of formula III are either commercially available or can be prepared by methods analogues to those described in the literature e.g. Wipf, Peter; Manojlovic, Marija D. Beilstein Journal of Organic Chemistry (201 1 ), 7, 824-830, Yoshimitsu, Y. et al. Journal of Organic Chemistry (2010), 75(1 1 ), 3843-3846, Shiau, T. P. et al. Bioorganic & Medicinal Chemistry Letters (2009), 19(4), 1 1 10-1 1 14.
Compounds of formula I, wherein R2 is not hydrogen, can be prepared by the alkylation of a compounds of formula IV, wherein R2 is hydrogen, with an alkyl halide of formula V as shown in scheme 2. Scheme 2
IV V
This reaction is typically carried out in a suitable solvent, such as dimethyl- formannide, dimethylacetannide, tetrahydrofuran or acetonitrile, in the presence of a suitable base such as a carbonate base, e.g. potassium carbonate, or a tertiary amine base, e.g. triethylamine or diisopropylethylamine, or a strong base such as sodium hydride at a temperature ranging from about 0° C to about 100° C.
The invention disclosed herein is further illustrated by the following non-limiting examples.
General Methods
Analytical LC-MS data were obtained using the methods identified below.
Method 1 : An Agilent 1200 LCMS system with ELS detector was used. Column: Agilent TC-C18 5 μιτι; 2.1x50 mm; Column temperature: 50°C; Solvent system: A = water/trifluoroacetic acid (99.9:0.1 ) and B = acetonitrile /trifluoroacetic acid (99.95:0.05); Method: Linear gradient elution with A:B = 99:1 to 0:100 in 4.0 minutes and with a flow rate of 0.8 mL/minute.
Method 2: An Agilent 1200 LCMS system with ELS detector was used. Column: XBridge ShieldRP18, 5 μιτι, 50x2.1 mm; Column temperature: 40°C; Solvent system: A = water/NH3 *H2O (99.95:0.05) and B = acetonitrile; Method: Linear gradient elution with A:B = 95:5 to 0:100 in 3.4 minutes and with a flow rate of 0.8 mL/minute. Method 3: An Agilent 1200 LCMS system with ELS detector was used. Column: XBridge ShieldRP18, 5 μιτι, 50x2.1 mm; Column temperature: 40°C; Solvent system: A = water/NH3 *H2O (99.95:0.05) and B = acetonitrile; Method: Linear gradient elution with A:B = 99:1 to 0:100 in 3.4 minutes and with a flow rate of 0.8 mL/minute. Method 4: An Agilent 1 100 LCMS system with ELS detector was used. Column: YMC ODS-AQ, 5 μιτι, 50x2.0mm; Column temperature: 50°C; Solvent system: A =0.1 % TFA in water and B = 0.05% TFA in Acetonitrile; Method: Linear gradient elution with A:B = 99:1 to 5:95 in 3.5 minutes and with a flow rate of 0.8 mL/minute.
Method 5: An Agilent 1200 LCMS system with ELS detector was used. Column: Agilent TC-C18 5 μιτι; 2.1x50mm; Column temperature: 50 °C; Solvent system: A = water/trifluoroacetic acid (99.9:0.1 ) and B = acetonitrile /trifluoroacetic acid (99.95:0.05); Method: Linear gradient elution with A:B = 90:10 to 0:100 in 4.0 minutes and with a flow rate of 0.8 mL min.
Preparative LC-MS-purification was performed on a PE Sciex API 150EX instrument with atmospheric pressure chemical ionization. Column: 50 X 20 mm YMC ODS-A with 5 μιτι particle size; Solvent system: A = water/trifluoroacetic acid (99.965:0.035) and B = acetonitrile /water/trifluoroacetic acid (94.965:5:0.035); Method: Linear gradient elution with A:B = 80:20 to 0:100 in 7 minutes and with a flow rate of 22.7 mL/minute. Fraction collection was performed by split-flow MS detection. Preparative SFC was performed on a Thar 80 instrument. Exemplified conditions can be, but not limited to: Column AD 250 X 30mm with 20 μιτι particle size; Column temperature: 38 °C, Mobile phase: Supercritical CO2/ EtOH(0.2%NH3H2O) =45/55.
Synthesis of intermediate I:
4-Chloro-8-fluoro-7-methoxyquinazoline: Step 1 : Commercial available (CAS 1180497-45-3) 2-amino-3-fluoro-4- methoxybenzoic acid (8 g, 43.21 mmol) and ammonium acetate (67 g, 864 mol) in trimethoxymethane (250 mL) were stirred at 100°C for 12 hrs. The mixture was filtered and washed with water (3x20 mL), the white solid was dried under vacuum to give 8-fluoro-7-methoxyquinazolin-4(3H)-one (8 g, 95%).
Step 2: To a mixture of 8-fluoro-7-methoxyquinazolin-4(3H)-one (4.0 g, 20.6 mmol) and diisopropylethylamine (11 g, 82 mmol) in toluene (100 mL) was added POCI3 (6.32g, 41 .2mmol) at 0°C. The reaction was stirred at 100°C for 12 hrs. The mixture was then cooled to 20°C and poured into ice-water (100 mL). The water phase was extracted with dichloromethane (3x 1 00 mL). The combined organic phases were washed with brine (3x 1 0 mL) and concentrated under vacuum. The residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give 4-chloro-8-fluoro-7-methoxyquinazoline 3 g (70%). Example 1 :
8-Fluoro-7-methoxy-W-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine:
A mixture of 4-chloro-8-fluoro-7-methoxyquinazoline (560 mg, 2.63 mmol), (+/-)-3- methyltetrahydrofuran-3-amine hydrochloride (400 mg, 2.92 mmol) and K2CO3 (800 mg, 5.84 mmol) in DMSO (30 mL) was stirred at 100°C for 1 2 hours. The solution was then poured into ice-water (100 mL) and extracted with dichloromethane (3x50 mL). The combined organic phases were washed with brine (3x 1 0 mL), dried over MgSO4 and concentrated under vacuum. The residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give (+/-)-8-fluoro-7-methoxy-/V-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine 320 mg (44%). The racemic mixture (320 mg) was purified by SFC (Column : AY
(250mm*30mm,5um)) separation and numbered according to the order of elution:
Stereoisomer 1 (first eluting by SFC): 140 mg 1H NMR (CDCIs, 400 MHz): δ 8.66 (s, 1 H), 7.44 (d, J = 8.8 Hz, 1 H), 7.19 (t, J = 8.4 Hz, 1 H), 5.68 (s, 1 H), 4.16 (d, J = 9.2 Hz, 1 H), 4.05 (s, 3H), 4.02-3.98 (m, 2H), 3.87 (d, J = 9.2 Hz, 1 H), 2.66-2.60 (m, 1 H), 2.17-2.09 (m, 1 H), 1 .75 (s, 3H).
LC-MS: {m/z) 278.1 (MH+) tR (minutes, method 1 ) = 1 .84 minutes.
[a]20D =18 ° (c = 0.1 mg/mL, methanol).
Stereoisomer 2 (second eluting by SFC): 160 mg
1H NMR (CDCI3, 400 MHz): δ 8.66 (s, 1 H), 7.44 (dd, J = 8.8, 1 .6 Hz, 1 H), 7.19 (t, J = 8.4 Hz, 1 H), 5.70 (s, 1 H), 4.16 (d, J = 9.2 Hz, 1 H), 4.05 (s, 3H), 4.02-3.98 (m, 2H), 3.87 (d, J = 9.2 Hz, 1 H), 2.66-2.60 (m, 1 H), 2.16-2.09 (m, 1 H), 1 .75 (s, 3H).
LC-MS: {m/z) 278.1 (MH+) tR (minutes, method 1 ) = 1 .84 minutes.
[a]20D = -26 ° (c = 0.1 mg/mL, methanol)
Example 2:
8-Fluoro-7-methoxy-W-methyl-W-(tetrahydrofuran-3-yl)quinazolin-4-amine:
Step 1 : A solution of 4-chloro-8-fluoro-7-methoxyquinazoline (440 mg, 2.06 mmol), tetrahydrofuran-3-amine (200 mg, 2.29 mmol) and diisopropylethylamine (600 mg, 4.58 mmol) in DMF (30 mL) was stirred at 100°C for 12 hrs. The solution was concentrated under vacuum, and the residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give 8-fluoro-7- methoxy-/V-(tetrahydrofuran-3-yl)quinazolin-4-amine 500 mg (83%) as a white solid. Step 2: To a solution of 8-fluoro-7-methoxy-/V-(tetrahydrofuran-3-yl)quinazolin-4- amine (480 mg, 1 .83 mmol) in THF (20 mL) was added a 60% suspension of NaH in mineral oil (100 mg, 2.74 mmol) at 0°C, then it was stirred at 0°C for 30 min and then allowed to warm to room temperature. Methyl iodide (388 mg, 2.74 mmol) was added at 20°C and the reaction was stirred at 20°C for 12 hrs. The solution was quenched with sat. aq. NH CI (2 mL), then concentrated under vacuum. The residue was diluted with dichloromethane (100 mL), washed with brine (3x10 mL), dried over MgSO4 and concentrated under vacuum. The crude product was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give 8-fluoro-7-methoxy-/V-methyl-/V-(tetrahydrofuran-3-yl)quinazolin-4-amine 230 mg (46%). The mixture of stereoisomers (230 mg) was purified by SFC (Column : AD-H
(250mm*30mm,5um)) separation and numbered according to the order of elution:
Stereoisomer 1 (first eluting by SFC): 75 mg
1H NMR (CDCI3, 400 MHz): δ 8.66 (s, 1 H), 7.77-7.74 (m, 1 H), 7.19-7.15 (m, 1 H), 5.29-5.23 (m, 1 H), 4.17-4.12 (m, 1 H), 4.07 (s, 3H), 3.99 (d, J = 5.6 Hz, 2H), 3.75 (q, J = 7.6 Hz, 1 H), 3.32 (s, 3H), 2.49-2.44 (m, 1 H), 2.12-2.08 (m, 1 H).
LC-MS: {m/z) 278.1 (MH+) tR (minutes, method 1 ) = 1 .78 minutes.
[a]20D = -15 ° (c = 0.1 mg/mL, methanol)
Stereoisomer 2 (second eluting by SFC): 80 mg
1H NMR (CDCI3, 400 MHz): δ 8.66 (s, 1 H), 7.76 (dd, J = 9.2, 2.0 Hz, 1 H), 7.18 (dd, J = 9.2, 8.0 Hz, 1 H), 5.31 -5.23 (m, 1 H), 4.17-4.12 (m, 1 H), 4.06 (s, 3H), 3.99 (d, J = 5.6 Hz, 2H), 3.75 (q, J = 7.6 Hz, 1 H), 3.32 (s, 3H), 2.48-2.44 (m, 1 H), 2.12-2.08 (m, 1 H). LC-MS: {m/z) 278.1 (MH+) tR (minutes, method 1 ) = 1 .79 minutes. [a]20D = 16 ° (c = 0.1 mg/mL, methanol)
Example 3
8-Fluoro-7-methoxy-W-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine:
A solution of 4-chloro-8-fluoro-7-methoxyquinazoline (500 mg, 2.35 mmol), 2- methyltetrahydrofuran-3-amine hydrochloride (388 mg, 2.82 mmol) and diisopropylethylannine (607 mg, 4.70 mmol) in DMF (20 mL) was stirred at 100°C for 12 hours. The solution was concentrated under vacuum, and the residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give a 8-fluoro-7-methoxy-/V-(2-methyltetrahydrofuran-3- yl)quinazolin-4-amine as a mixture of all four possible stereoisomers 600 mg (84%). The mixture of stereoisomers (600 mg) was purified by SFC (Column : AD (250mm*30mm,5um)) separation and numbered according to the order of elution:
Stereoisomer 1 (first eluting by SFC): 180 mg
1H NMR (CDCIs, 400 MHz): δ 8.66 (s, 1 H), 7.47 (dd, J = 8.8, 1 .2 Hz, 1 H), 7.21 (t, J = 8.8 Hz, 1 H), 5.72 (d, J = 6.8 Hz, 1 H), 4.64-4.58 (m, 1 H), 4.09-3.98 (m, 6H), 2.59-2.50 (m, 1 H), 2.00-1 .96 (m, 1 H), 1 .36 (d, J = 6.4 Hz, 3H).
LC-MS: {m/z) 278.1 (MH+) tR (minutes, method 1 ) = 1 .84 minutes.
[a]20D = -23 ° (c = 0.1 mg/mL, methanol) Stereoisomer 2 (second eluting by SFC): 80 mg
1H NMR (CDCI3, 400 MHz): δ 8.65 (s, 1 H), 7.48 (dd, J = 9.2, 1 .6 Hz, 1 H), 7.24-7.20 (m, 1 H), 5.68 (d, J = 8.4 Hz, 1 H), 5.07-5.02 (m, 1 H), 4.1 1 -4.01 (m, 5H), 3.85-3.82 (m, 1 H), 2.56-2.50 (m, 1 H), 2.03-1 .99 (m, 1 H), 1 .26 (d, J = 6.0 Hz, 3H). LC-MS: {m/z) 278.1 (MH+) tR (minutes, method 1 ) = 1 .82 minutes.
[a]20D = 22 ° (c = 0.1 mg/mL, methanol)
Stereoisomer 3 (third eluting by SFC): 180 mg
1H NMR (CDCI3, 400 MHz): 5 8.64 (s, 1 H), 7.48 (dd, J = 9.2, 1 .6 Hz, 1 H), 7.24-7.19 (m, 1 H), 5.71 (d, J = 8.4 Hz, 1 H), 5.07-5.02 (m, 1 H), 4.1 1 -4.01 (m, 5H), 3.85-3.82 (m, 1 H), 2.56-2.50 (m, 1 H), 2.03-1 .97 (m, 1 H), 1 .26 (d, J = 6.4 Hz, 3H).
LC-MS: {m/z) 278.1 (MH+) tR (minutes, method 1 ) = 1 .81 minutes.
[a]20D = -2 1 0 (c = 0.1 mg/mL, methanol)
Stereoisomer 4 (fourth eluting by SFC): 80 mg
1H NMR (CDCI3, 400 MHz): δ 8.66 (s, 1 H), 7.47 (dd, J = 8.8, 1 .2 Hz, 1 H), 7.21 (t, J = 8.8 Hz, 1 H), 5.72 (6, J = 1.2 Hz, 1 H), 4.64-4.60 (m, 1 H), 4.09-3.98 (m, 6H), 2.59-2.50 (m, 1 H), 2.00-1 .93 (m, 1 H), 1 .36 (d, J = 6.4 Hz, 3H).
LC-MS: {m/z) 278.1 (MH+) tR (minutes, method 1 ) = 1 .85 minutes. [a]20D = 340 (c = 0.1 mg/mL, methanol) S nthesis of intermediate II:
4,8-dichloro-7-nnethoxyquinazoline
Step 1: To the suspension of commercial available (CAS 33234-36-5) 2-chloro-3- methoxybenzoic acid (19.5 g, 104 mmol) in acetic acid (100 mL) and H2O (100 mL) at room temperature was added bromine (10.8 mL, 209 mmol) dropwise. The resulting mixture was heated at 60°C overnight. Then cooled to room temperature and extracted with dichloromethane (3x200 mL). The combined organic phases were washed with water (3x300 mL), dried over Na2SO4, filtered and concentrated to give 6-bromo-2-chloro-3-methoxybenzoic acid 23 g (83%).
Step 2: To as suspension of 6-bromo-2-chloro-3-methoxybenzoic acid (10 g, 38 mmol) in toluene (200 mL) was added diphenylphosphoryl azide (12.2 mL, 56.6 mmol) triethylamine (15.8 mL, 113 mmol) and tert-butanol (18.0 ml, 188 mmol). The reaction mixture was heated at 100°C for 2 hrs under N2. The mixture was evaporated and the residue was diluted with ethyl acetate. The organic phase was washed with 5% aqueous citric acid solution, water, sat. aq. NaHCO3, brine, dried over Na2SO4, and concentrated. The crude product was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether, yielding tert-butyl (6-bromo-2-chloro-3-methoxyphenyl)carbamate 12 g (95%).
Step 3: To an ice-cold solution of tert-butyl (6-bromo-2-chloro-3- methoxyphenyl)carbamate (12 g, 37 mmol) in dichloromethane (150 mL) was added trifluoroacetic acid (20 mL). The mixture was warmed to room temperature and stirred for 5 hrs. The solution was then concentrated and the residue was diluted with dichloromethane, adjusted to pH=9 by sat. aq. NaHCO3, washed with water, dried over Na2SO4, filtered and concentrated to give 6-bromo-2-chloro-3-methoxyaniline 8.3 g (98%). Step 4: To a solution of 6-bromo-2-chloro-3-nnethoxyaniline (8.3 g, 35 mmol) in methanol (300 mL) was added 1 ,3-bis(diphenylphosphino)propane (2.90 g, 7.02 mmol), Pd(AcO)2 (1 .58 g, 7.02 mmol) and t ethylamine (4.89 mL, 35.1 mmol). The reaction mixture was stirred at 100°C under an atmosphere of CO (3 MPa) for 2 days. The mixture was cooled to room temperature and filtered. The filtrate was concentrated and the residue was dissolved in dichloromethane. The resulting solution was washed with water, dried over Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to yield methyl 2-amino-3-chloro-4- methoxybenzoate 5.0 g (65%).
Step 5: To a solution of methyl 2-amino-3-chloro-4-methoxybenzoate (4.95 g, 23.0 mmol) in a mixture of THF (60 mL) and H2O (30 mL) was added LiOH H2O (2.89 g, 68.8 mmol). The mixture was heated at 50°C for 3 days. The mixture was then cooled to room temperature and extracted with ethyl acetate. The aqueous phase was acidified by aq. KHSO4 until pH=3, filtered, and the filter cake was collected, washed with water and dried to give 2-amino-3-chloro-4-methoxybenzoic acid 3.2 g (69%).
Step 6: To a solution of 2-amino-3-chloro-4-methoxybenzoic acid (700 mg, 3.47 mmol) in CH(OMe)3 (40 mL) was added ammonium acetate (5.35 g, 69.4 mmol). The mixture was then heated at 90°C overnight. The reaction was cooled to room temperature, filtered and the filter cake was collected, washed with water and dried to give 8-chloro-7-methoxyquinazolin-4(3H)-one 630 mg (86%).
Step 7: To an ice-cold solution of 8-chloro-7-methoxyquinazolin-4(3H)-one (630 mg, 2.99 mmol) in toluene (15 mL) was dropwise added POCI3 (0.56 mL, 6.0 mmol) and diisopropylethylamine (2.08 mL, 12.0 mmol). The mixture was heated at 100°C overnight, then cooled to room temperature and carefully poured into ice-water. The water phase was extracted with dichloromethane (2x30 mL). The combined organic phases were washed with water, dried over Na2SO4, filtered, concentrated in vacuo. The crude product was purified by flash chromatography on silica gel using a gradient of dichloromethane and ethyl acetate to give 4,8-dichloro-7- methoxyquinazoline 580 mg (85%).
Example 4:
8-Chloro-7-methoxy-W-(tetrahydrofuran-3-yl)quinazolin-4-amine:
To a solution of 4,8-dichloro-7-methoxyquinazoline (650 mg, 2.84 mmol) in dimethylformamide (20 mL) was added tetrahydrofuran-3-amine (297 mg, 3.41 mmol) and diisopropylethylannine (0.99 mL, 5.7 mmol). Through the mixture was bubbled N2 for 5 minutes. The reaction was then heated at 100°C for 3 hrs under an atmosphere of N2. The crude mixture was concentrated and the residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give 8-chloro-7-methoxy-/V-(tetrahydrofuran-3-yl)quinazolin-4-amine 650 mg (82%).
The racemic mixture (650 mg) was purified by SFC (Column : Chiral Pak AD 5μηη, Daicel Chemical Industries, Ltd, 250x30mm I.D.) separation and numbered according to the order of elution:
Stereoisomer 1 (first eluting by SFC): 200 mg
1H NMR (CD3OD, 400 MHz): δ 8.45 (s, 1 H), 8.20 (d, J =9.29 Hz, 1 H), 7.38 (d, J =9.29 Hz, 1 H), 3.99-4.07 (m, 5H), 3.77-3.89 (m, 2H), 2.32-2.42 (m, 1 H), 2.04-2.14 (m, 1 H). LC-MS: {m/z) 280.1 (MH+) tR (minutes, method 2) = 1 .58 minutes [a]D M +38.3° (c = 0.10, methanol).
Stereoisomer 2 (second eluting by SFC): 200 mg
1H NMR (CD3OD, 400 MHZ): δ 8.45 (s, 1 H), 8.20 (d, J =9.29 Hz, 1 H), 7.38 (d, J =9.05 Hz, 1 H), 3.99-4.07 (m, 5H), 3.77-3.89 (m, 2H), 2.32-2.42 (m, 1 H), 2.04-2.14 (m, 1 H).
LC-MS: {m/z) 280.1 (MH+) tR (minutes, method 1 ) = 1 .57 minutes [a] D 20 -32.0° (c = 0.10, methanol).
Exam le 5
8-Chloro-7-methoxy-W-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine:
To a solution of 4,8-dichloro-7-methoxyquinazoline (450 mg, 1 .96 mmol) in DMF (20 mL) was added 2-methyltetrahydrofuran-3-amine (mixture of all 4 stereoisomers) (322 mg, 2.36 mmol) and diisopropylethylamine (1 .03 mL, 5.89 mmol). Through the mixture was bubbled N2 for 5 minutes and it was then heated at 100°C overnight. The crude mixture was concentrated and the residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to yield 8-chloro-7-methoxy-/V-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine 450 mg (78%) as a mixture of all four possible stereoisomers.
A mixture of stereoisomers (750 mg) was purified by SFC separation (column: Chiral Pak AD 5μηη ,Daicel Chemical Industries, Ltd) and numbered according to the order of elution: Stereoisomer 1 (first eluting by SFC): 131 mg
1H NMR (CD3OD, 400 MHz): 58.45 (s, 1H), 8.19 (d, J =9.6 Hz, 1H), 7.39 (d, J =9.2 Hz, 1H), 4.52-4.57 (m, 1H), 4.04 (s, 4H), 3.97-4.02 (m, 2H), 2.41-2.50 (m, 1H), 1.97-2.04 (m, 1 H), 1.32 (d, J =6.4 Hz, 3H). LC-MS: {m/z) 294.1 (MH+) tR (minutes, method 1 ) = 1.93 minutes
[a]D 20= -59.3° (c = 0.10, methanol).
Stereoisomer 2 (second eluting by SFC): 97 mg
1H NMR (CD3OD, 400 MHz): δ 8.43 (s, 1 H), 8.25 (d, J =9.2 Hz, 1 H), 7.39 (d, J =9.6 Hz, 1H), 5.01-5.06 (m, 1H), 4.09-4.14 (m, 2H), 4.04 (s, 3H), 3.72 (q, J =8.0 Hz, 3H),
2.40- 2.46 (m, 1H), 2.10-2.14 (m, 1H), 1.09 (d, J=6.0 Hz, 3H).
LC-MS: {m/z) 294.1 (MH+) tR (minutes, method 2) = 1.73 minutes [a]D 20= -28.3° (c = 0.10, methanol).
Stereoisomer 3 (third eluting by SFC): 37 mg
1H NMR (CD3OD varian 400): δ 8.43 (s, 1 H), 8.24 (d, J =9.2 Hz, 1 H), 7.38 (d, J =9.2 Hz, 1H), 5.00-5.05 (m, 1H), 4.10-4.14 (m, 2H), 4.04 (s, 3H), 3.72 (q, J =8.0 Hz, 3H),
2.41- 2.46 (m, 1H), 2.09-2.14 (m, 1H), 1.09 (d, J=6.4 Hz, 3H).
LC-MS: {m/z) 294.1 (MH+) tR (minutes, method 1) = 1.73 minutes [a]D 20= +29.3° (c = 0.10, methanol).
Stereoisomer 4 (fourth eluting by SFC): 50 mg
1H NMR (H000269489 H20773-029-4A MeOD varian 400): δ 8.46 (s, 1H), 8.20 (d, J =9.2 Hz, 1H), 7.39 (d, J =9.2 Hz, 1H), 4.53-4.57 (m, 1H), 4.04 (s, 3H), 3.97-4.02 (m, 3H), 2.43-2.48 (m, 1 H), 1.99-2.04 (m, 1 H), 1.32 (d, J =6.4 Hz, 3H). LC-MS: {m/z) 294.1 (MH+) tR (minutes, method 1 ) = 1 .77 minutes [a]D 20= +62.7° (c = 0.10, methanol).
Example 6
8-Chloro-7-methoxy-W-methyl-W-(tetrahydrofuran-3-yl)quinazolin-4-amine, stereoisomer 1 :
To an ice-cold solution of stereoisomer 1 of 8-chloro-7-methoxy-/V-(tetrahydrofuran- 3-yl)quinazolin-4-amine (150 mg, 0.54 mmol) in a mixture of THF (4 mL) and dimethylformamide (2 mL) was added NaH (32 mg, 0.81 mmol, 60% in mineral oil). The mixture was stirred at 0°C for 30 minutes. Then methyliodide (100 mg, 0.70 mmol) was added at 0°C. The reaction was stirred at room temperature for 3 hours and then quenched with sat. NH CI (aq) (2 mL). The crude reaction mixture was concentrated and the residue purified by preparatory TLC (dichloromethane/methanol=50/1 ) to give 8-chloro-7-methoxy-/V-methyl-/V- (tetrahydrofuran-3-yl)quinazolin-4-amine (stereoisomer 1 ).
23 mg (14%)
1H NMR (CD3OD, 400 MHz): δ 8.49 (s, 1 H), 8.11 (d, J =9.6 Hz, 1 H), 7.39 (d, J =9.6 Hz, 1 H), 5.24-5.30 (m, 1 H), 4.10-4.13 (m, 1 H), 4.06 (s, 3H), 3.94-3.98 (m, 2H), 3.73 (q, J =8.0 Hz, 1 H), 3.34 (s, 3H), 2.45-2.49 (m, 1 H), 2.13-2.18 (m, 1 H).
LC-MS: {m/z) 294.0 (MH+) tR (minutes, method 3) = 2.55 minutes
[a]D 20 =19.3° (c = 0.10, CHCI3) 8-Chloro-7-methoxy-W-methyl-W-(tetrahydrofuran-3-yl)quinazolin-4-amine, stereoisomer 2 To an ice-cold solution of stereoisomer 2 of 8-chloro-7-methoxy-/V-(tetrahydrofuran- 3-yl)quinazolin-4-amine (150 mg, 0.54 mmol) in a mixture of THF (4 ml_) and DMF (2 ml_) was added NaH (32 mg, 0.81 mmol, 60% in mineral oil). The reaction was stirred at 0°C for 30 minutes Then CH3I (100 mg, 0.70 mmol) was added at 0°C. The reaction was allowed to warm to RT and stirred for 3 hours. The reaction was quenched with sat. NH CI (aq) (2 ml_). Then concentrated and the residue was purified by preparatory TLC (dichloromethane/methanol=50/1 ) give stereoisomer 2 of 8-chloro-7-methoxy-/V-methyl-/V-(tetrahydrofuran-3-yl)quinazolin-4-amine. 25 mg (16%)
1H NMR (H000271637 H20773-033-2B MeOD varian 400): 5 8.49 (s, 1 H), 8.11 (d, J =9.6 Hz, 1 H), 7.40 (d, J =9.6 Hz, 1 H), 5.24-5.31 (m, 1 H), 4.10-4.13 (m, 1 H), 4.06 (s, 3H), 3.94-3.98 (m, 2H), 3.73 (q, J =7.6Hz, 1 H), 3.34 (s, 3H), 2.44-2.49 (m, 1 H), 2.13-2.18 (m, 1 H).
LC-MS: {m/z) 294.0 (MH+) tR (minutes, method 1 ) = 2.1 1 minutes
[a]D 20 =-7.7° (c = 0.10, CHCIs).
Example 7
8-Chloro-7-methoxy-W-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine:
To a solution of 4,8-dichloro-7-methoxyquinazoline (350 mg, 1 .53 mmol) in DMSO (30 ml_) was added 3-methyltetrahydrofuran-3-amine (210 mg, 1 .53 mmol) and NaHCO3 (257 mg, 3.06 mmol). The mixture was heated at 100°C for 3 hours. Then cooled to room temperature and quenched with H2O (10 ml_). The resulting mixture was extracted with dichloromethane (3x20 ml). The combined organic phases were washed with H2O (50 ml_), dried over Na2SO4, filtered, and concentrated. The residue was purified by prep-HPLC to give 8-chloro-7-methoxy-/V-(3- methyltetrahydrofuran-3-yl)quinazolin-4-annine 200 mg (45%).
The racemic mixture (200 mg) was purified by SFC (Column: Chiralpak AD
250x30mm I.D.,5um) separation and numbered according to the order of elution:
Stereoisomer 1 (first eluting by SFC): 43 mg
1H NMR (CD3OD, 400 MHz): δ 8.46 (s, 1 H), 8.21 (d, J =9.2 Hz, 1 H), 7.39 (d, J =9.6 Hz, 1 H), 4.19 (d, J =9.2 Hz, 1 H), 4.04 (s, 3H), 3.93-3.99 (m, 3H), 2.56-2.62 (m, 1 H), 2.13-2.20 (m, 1 H), 1 .67 (s, 3H). LC-MS: {m/z) 294.0 (MH+) tR (minutes, method 4) = 2.16 minutes
[a]D 20= +8.3° (c = 0.10, CHCI3).
Stereoisomer 2 (second eluting by SFC): 39 mg
1H NMR (CD3OD, 400): δ 8.46 (s, 1 H), 8.21 (d, J =9.2 Hz, 1 H), 7.39 (d, J =9.2 Hz, 1 H), 4.19 (d, J =9.2 Hz, 1 H), 4.04 (s, 3H), 3.93-3.99 (m, 3H), 2.56-2.62 (m, 1 H), 2.13-2.20 (m, 1 H), 1 .67 (s, 3H).
LC-MS: {m/z) 294.0 (MH+) tR (minutes, method 4) = 2.17 minutes [a]D 20= -5.7° (c = 0.10, CHCI3).
Example 8
Cis-4-(8-fluoro-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole: A mixture of 4-chloro-8-fluoro-7-methoxyquinazoline (320 mg, 1 .50 mmol), cis- hexahydro-2H-furo[3,2-b]pyrrole (200 mg, 1 .77 mmol) and diisopropylethylamine (457 mg, 3.54 mmol) in DMF (30 mL) was stirred at 100 °C for 12 hrs. The solution was concentrated in vacuo, the residue was diluted with dichloromethane (100 mL), washed with brine (3x10 mL), dried and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give racemic cis-4-(8-fluoro-7-methoxyquinazolin-4- yl)hexahydro-2H-furo[3,2-b]pyrrole (300 mg, 69%).
The racemate of cis-4-(8-fluoro-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2- b]pyrrole (300 mg) was purified by SFC (Column: IC (250mm*30mm,10um)) separation and numbered according to the order of elution:
Stereoisomer 1 :
100 mg (33%) 1H NMR (CDCIs, 400 MHz): 5 8.62 (s, 1 H), 7.90 (dd, J =9.2,1 .6 Hz, 1 H), 7.15 (t, J = 8.8 Hz, 1 H), 5.15 (t, J =4.9 Hz, 1 H), 4.60 (d, J = 4.2 Hz, 1 H), 4.1 1 -4.09 (m, 2H), 4.06 (s, 3H), 3.95-3.91 (m, 2H), 2.44-2.33 (m, 2H), 2.18-2.15 (m, 1 H), 2.04-2.01 (m, 1 H).
LC-MS (m/z) 290.1 (MH+) tR (minutes, method 1 ) = 1 .81
[a]D 20 +181 .3° (c = 0.10, methanol). Stereoisomer 2:
100 mg (33%)
1H NMR (CDCI3, 400 MHz): δ 8.63 (s, 1 H), 7.91 (dd, J = 9.2, 1 .6 Hz, 1 H), 7.15 (t, J = 8.8 Hz, 1 H), 5.15 (t, J = 4.8 Hz, 1 H), 4.60 (t, J = 4.4 Hz, 1 H), 4.12-4.09 (m, 2H), 4.06 (s, 3H), 3.95-3.91 (m, 2H), 2.44-2.33 (m, 2H), 2.18-2.15 (m, 1 H), 2.04-2.01 (m, 1 H). LC-MS (m/z) 290.1 (MH+) tR (minutes, method 1 ) = 1 .80.
[a]D 20 -202° (c = 0.10, methanol). Example 9
Cis-4-(8-chloro-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole:
To a solution of 4,8-dichloro-7-methoxyquinazoline (350 mg, 1 .53 mmol) in DMF (12 ml_) was added hexahydro-2H-furo[3,2-b]pyrrole (208 mg, 1 .84 mmol) and diisopropylethylamine (0.54 ml_, 3.0 mmol). Nitrogen was bubbled through the mixture for 2 min and it was heated at 100 °C overnight. The reaction was concentrated in vacuo, suspended in ethyl acetate and stirred for 1 hr at room temperature. The solid was filtered off and washed with ethyl acetate to give 4-(8- chloro-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole (400 mg, 99%). The racemate of 4-(8-chloro-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2- b]pyrrole (400 mg) was purified by SFC (Column: Chiral Cel OJ 20μηη, Daicel Chemical Industries, Ltd 250x30mm I.D) separation and numbered according to the order of elution: Stereoisomer 1
106 mg, (26.5%)
1H NMR (CD3OD, 400 MHz): δ 8.47 (s, 1 H), 8.31 (d, J =9.2 Hz, 1 H), 7.40 (d, J =9.6 Hz, 1 H), 5.20 (t, J =4.8 Hz, 1 H), 4.61 (t, J =4.0 Hz, 1 H), 4.14-4.18 (m, 2H), 4.08 (s, 3H), 3.92-3.95 (m, 2H), 2.43-2.48 (m, 1 H), 2.29-2.32 (m, 1 H), 2.07-2.13 (m, 1 H). LC-MS (m/z) 306.1 (MH+) tR (minutes, method 1 ) = 1 .88
[a]D 20 +280° (c = 0.10, methanol).
Stereoisomer 2:
102 mg (25.5%) 1H NMR (CD3OD, 400 MHz): δ 8.44 (s, 1 H), 8.28 (d, J =9.6 Hz, 1 H), 7.37 (d, J =9.6 Hz, 1 H), 5.17 (t, J =4.8 Hz, 1 H), 4.59 (t, J =4.0 Hz, 1 H), 4.09-4.15 (m, 2H), 4.05 (s, 3H), 3.87-3.94 (m, 2H), 2.37-2.48 (m, 1 H), 2.24-2.32 (m, 1 H), 1 .99-2.15 (m, 1 H).
LC-MS (m/z) 306.1 (MH+) tR (minutes, method 1 ) = 1 .89 [a]D 20 -301 ° (c = 0.10, methanol).
Intermediate III
8-Bromo-4-chloro-7-methoxyquinazoline:
Step 1 : To a suspension of 2-amino-3-bromo-4-methoxybenzoic acid (CAS1 180497- 47-5) (5.50 g, 22.4 mmol) in trimethoxymethane (100 mL) was added NH4OAc (17.2 g, 224 mmol). The mixture was heated at 90 °C for 12 hrs. The mixture was cooled to 25°C, the solid was filtered off, washed with H2O (50 mL) and dried in vacuo to give 8-bromo-7-methoxyquinazolin-4(3H)-one 3.50 g (61 .4%).
Step 2: To an ice-cold solution of 8-bromo-7-methoxyquinazolin-4(3H)-one (3.50 g, 13.7 mmol) in dry toluene (50 mL) was added diisopropylethylamine (7.09 g, 54.9 mmol) and POCI3 (18 g, 0.12 mol) dropwise. The mixture was heated at 100 °C for 12 hrs, then cooled to 25 °C and poured into H2O (100 mL). The aqueous layer was extracted with dichloromethane (100 mL). The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel using a gradient of dichloromethane and ethyl acetate to give 8-bromo-4-chloro-7-methoxyquinazoline 2.4 g, (64%).
Example 10
Cis-4-(8^romo-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole:
To a solution of 8-bromo-4-chloro-7-methoxyquinazoline (1 .30 g, 4.75 mmol) in dry dimethylformannide (20 mL) was added hexahydro-2H-furo[3,2-b]pyrrole (860 mg, 7.60 mmol) and diisopropylethylamine (1 .84 g, 14.3 mmol). Nitrogen was bubbled through the mixture for 5 min and it was heated at 100 °C for 12 hrs under N2. The mixture was concentrated in vacuo, the residue was dissolved in dichloromethane (50 mL). The mixture was adjusted to pH 8 by sat. aq. NaHCO3. The aqueous layer was extracted with dichloromethane (50 mL). The combined organic phases were dried over Na2SO4, filtered and concentrated. The crude product was purified by chromatography on silica gel using a gradient of dichloromethane and ethyl acetate to give 4-(8-bromo-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole 1 .6 g (95%).
The racemate of cis-4-(8-bromo-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2- b]pyrrole (1 .6 g) was purified by SFC (Column : AD 250mm*50mm, 10um) separation and numbered according to the order of elution:
Stereoisomer 1 :
651 mg (39.3%)
1H NMR (CDCIs, 400 MHz): δ 8.70 (s, 1 H), 8.1 1 (d, J = 9.2 Hz, 1 H), 7.12 (d, J = 9.2 Hz, 1 H), 5.16-5.14 (m, 1 H), 4.58-4.55 (m, 1 H), 4.14-4.08 (m, 2H), 4.05 (s, 3 H), 3.94- 3.91 (m, 2H), 2.44-2.31 (m, 2H), 2.16-2.15 (m, 1 H), 2.03-1 .95 (m, 1 H).
LC-MS (m/z) 350.0 (MH+) tR (minutes, method 1 ) = 2.02
[a]D 20 +303° (c = 0.10, CHCI3)
Stereoisomer 2: 564 mg (35.2%)
1H NMR (CDCI3, 400 MHz): δ 8.70 (s, 1 H), 8.1 1 (d, J = 9.2 Hz, 1 H), 7.12 (d, J = 9.2 Hz, 1 H), 5.16-5.14 (m, 1 H), 4.58-4.56 (m, 1 H), 4.13-4.07 (m, 2H), 4.05 (s, 3 H), 3.94- 3.90 (m, 2H), 2.44-2.31 (m, 2H), 2.16-2.14 (m, 1 H), 2.01 -1 .98 (m, 1 H). LC-MS (m/z) 350.0 (MH+) tR (minutes, method 1 ) = 2.02 [a]D 20 -233° (c = 0.10, CHCI3)
Example 11
8-Chloro-7-methoxy-W-methyl-W-(3-methyltetrahydrofuran-3-yl)quinazolin-4- amine:
Stereoisomer 1
To an ice-cold solution of stereoisomer 2 of (example 7) 8-chloro-7-methoxy-/V-(3- methyltetrahydrofuran-3-yl)quinazolin-4-amine (200 mg, 0.681 mmol) in THF (10 mL) was added NaH (60% dispersion in mineral oil) (41 mg, 1 .0 mmol). The mixture was stirred at 0°C for 30 min. Then Mel (126 mg, 0.885 mmol) was added at 0 °C and it was stirred at 25°C for 3 hrs. H2O (5 mL) was added to the mixture and the THF was removed in vacuo. The residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with H2O (10 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by preparative TLC, eluting with dichloromethane/methanol=50/1 , to give stereoisomer 1 of 8-chloro-7-methoxy-/V-methyl-/V-(3-methyltetrahydrofuran-3-yl)quinazolin-4- amine 156 mg (70.7%). 1H NMR (CD3OD, 400 MHz): δ 8.49 (s, 1 H), 8.08 (d, J=9.2 Hz, 1 H), 7.39 (d, J=9.6 Hz, 1 H), 4.37 (d, J=8.8 Hz, 1 H), 4.05 (s, 3 H), 3.97 - 3.85 (m, 3 H), 3.35 (s, 3 H), 2.47 - 2.41 (m, 1 H), 2.31 - 2.27 (m, 1 H), 1 .69 (s, 3 H).
LC-MS (m/z) 308.1 (MH+) tR (minutes, method 1 ) = 1 .932
[a]D 20 +20.33° (c = 0.10, methanol). Stereoisomer 2 To an ice-cold solution of stereoisomer 1 of (example 7) 8-chloro-7-methoxy-/V-(3- methyltetrahydrofuran-3-yl)quinazolin-4-amine (200 mg, 0.681 mmol) in THF (10 mL) was added NaH (60% dispersion in mineral oil) (41 mg, 1 .0 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (126 mg, 0. 885 mmol) was added. The mixture was heated to 25 °C and stirred for 3 hrs. To the reaction mixture was added H2O (5 mL) and THF was removed in vacuo. The residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with water (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by preparative TLC, eluting with dichloromethane/methanol=50/1 , to give stereoisomer 2 of 8-chloro-7-methoxy-/V-methyl-/V-(3-methyltetrahydrofuran-3- yl)quinazolin-4-amine 141 mg (63.9%).
1H NMR (CD3OD, 400 MHz): δ 8.49 (s, 1 H), 8.08 (d, J=9.2 Hz, 1 H), 7.39 (d, J=9.6 Hz, 1 H), 4.37 (d, J=8.8 Hz, 1 H), 4.05 (s, 3 H), 3.97 - 3.85 (m, 3 H), 3.35 (s, 3 H), 2.47 - 2.44 (m, 1 H), 2.31 - 2.6 (m, 1 H), 1 .68 (s, 3 H). LC-MS (m/z) 308.1 (MH+) tR (minutes, method 1 ) = 1 .950
[a]D 20 -26.33° (c = 0.10, methanol).
Example 12
8-Chloro-/V-(2,3-dimethyltetrahydrofuran-3-yl)-7-methoxyquinazolin-4-amine: To a solution of 4,8-dichloro-7-methoxyquinazoline (1 .8 g, 7.9 mmol) in DMSO (30 mL) was added 2,3-dimethyltetrahydrofuran-3-amine (905 mg, 7.86 mmol) and NaHCO3 (660 mg, 7.86 mmol). The mixture was heated at 100 °C for 3 hrs and then cooled to 20 °C. H2O (30 mL) was added to the mixture, the precipitate was filtered off and washed with water (50 mL), dried and purified by flash chromatography on silica gel using a gradient of dichloromethane and methanol to give 8-chloro-/V-(2,3- dimethyltetrahydrofuran-3-yl)-7-methoxyquinazolin-4-amine (1 .2 g, 50 The mixture of all 4 stereoisomers of 8-chloro-/V-(2,3-dimethyltetrahydrofuran- 3-yl)-7-methoxyquinazolin-4-amine 2.4 g was purified by SFC (Column : AS 300mm*50nnnn, 10um). The stereoisomers were numbered according to their order of elution.
Stereoisomer 1 :
400 mg (15.8%)
1H NMR (CD3OD, 400 MHz): δ 8.47 (s, 1 H), 8.17 (d, J=9.2 Hz, 1 H), 7.38 (d, J=8.8 Hz, 1 H), 4.52 (q, J=6.4 Hz, 1 H), 4.04 (s, 3 H), 4.02 - 3.96 (m, 1 H), 3.86 (q, J=8.4 Hz, 1 H), 2.61 - 2.55 (m, 1 H), 2.19 - 2.13 (m, 1 H), 1 .65 (s, 3 H), 1 .06 (d, J=6.4 Hz, 3 H).
LC-MS (m/z) 308.1 (MH+) tR (minutes, method 5) = 1 .267
[a]D 20 +20.00° (c = 0.10, methanol).
Stereoisomer 2: 300 mg (1 1 .9%)
1H NMR (CD3OD, 400 MHz): δ 8.47 (s, 1 H), 8.16 (d, J=9.2 Hz, 1 H), 7.38 (d, J=9.6 Hz, 1 H), 4.51 (q, J=6.4 Hz, 1 H), 4.04 (s, 3 H), 4.02 - 3.97 (m, 1 H), 3.86 (q, J=8.4 Hz, 1 H), 2.61 - 2.55 (m, 1 H), 2.19 - 2.13 (m, 1 H), 1 .65 (s, 3 H), 1 .06 (d, J=6.4 Hz, 3 H). LC-MS (m/z) 308.1 (MH+) tR (minutes, method 5) = 1 .272 [a]D 20 -13.33° (c = 0.10, methanol). Stereoisomer 3: 600 mg (23.7%)
1H NMR (CD3OD, 400 MHz): δ 8.46 (s, 1 H), 8.20 (d, J=9.2 Hz, 1 H), 7.36 (d, J=9.2 Hz, 1 H), 4.47 (q, J=6.4 Hz, 1 H), 4.03 (s, 3 H), 3.99 - 3.90 (m, 2 H), 2.71 - 2.66 (m, 1 H), 2.26 - 2.21 (m, 1 H), 1 .57 (s, 3 H), 1 .26 (d, J=6.4 Hz, 3 H). LC-MS (m/z) 308.1 (MH+) tR (minutes, method 5) = 1 .295 [a]D 20 -25.33° (c = 0.10, methanol). Stereoisomer 4: 700 mg (27.7%) 1H NMR (CD3OD, 400 MHz): δ 8.46 (s, 1 H), 8.21 (d, J=9.2 Hz, 1 H), 7.36 (d, J=9.2 Hz, 1 H), 4.47 (q, J=6.4 Hz, 1 H), 4.04 (s, 3 H), 3.99 - 3.90 (m, 2 H), 2.71 - 2.66 (m, 1 H), 2.26 - 2.21 (m, 1 H), 1 .57 (s, 3 H), 1 .26 (d, J=6.4 Hz, 3 H).
LC-MS (m/z) 308.1 (MH+) tR (minutes, method 5) = 1 .30
[a]D 20 +43.67° (c = 0.10, methanol).
Example 13
8-Chloro-W-(2,3-dimethyltetrahydrofuran-3-yl)-7-methoxy-W-methylquinazolin 4-amine:
Stereoisomer 1 :
To an ice-cold solution of stereoisomer 1 example 12 (200 mg, 0.650 mmol) in THF (10 mL) was added NaH (60% dispersion in mineral oil) (39 mg, 0.98 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (120 mg, 0.845 mmol) was added. The reaction was allowed to warm to 25 °C and stirred for 3 hrs. H2O (5 mL) was added to the mixture and the THF was removed in vacuo. The residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with H2O (10 mL), dried over Na2SO4, concentrated in vacuo and purified by preparative TLC, using dichloromethane/methanol=5071 , to give stereoisomer 1 of 8- chloro-/V-(2,3-dimethyltetrahydrofuran-3-yl)-7-methoxy-/V-methylquinazolin-4-amine (1 18 mg, 57%).
1H NMR (CD3OD, 400 MHz): δ 8.54 (s, 1 H), 8.12 (d, J=9.2 Hz, 1 H), 7.46 (d, J=9.2 Hz, 1 H), 4.09 (s, 3 H), 4.07 - 4.04 (m, 1 H), 3.94 - 3.88 (m, 1 H), 3.40 (s, 3 H), 2.66 - 2.58 (m, 1 H), 2.26 - 2.21 (m, 1 H), 1 .73 (s, 3 H), 0.96 (d, J=6.4 Hz, 3 H).
LC-MS (m/z) 322.2 (MH+) tR (minutes, method 5) = 1 .46
[a]D 20 -9.67° (c = 0.10, methanol).
Stereoisomer 2: To an ice-cold solution of stereoisomer 2 example (200 mg, 0.650 mmol) in THF (10 ml_) was added NaH (60% dispersion in mineral oil) (39 mg, 0.98 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (120 mg, 0.845 mmol) was added. The reaction was stirred at 25 °C for 3 hrs and then H2O (5 ml_) was added. THF was removed in vacuo and the residue extracted with dichloromethane (2x20 ml_). The combined organic phases were washed with H2O (10 ml_), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by preparative TLC, using dichloromethane/methanol=50/1 , to give stereoisomer 2 of 8-chloro-/V-(2,3- dimethyltetrahydrofuran-3-yl)-7-methoxy-/V-methylquinazolin-4-amine (120 mg, 57%). 1H NMR (CD3OD, 400 MHz): δ 8.54 (s, 1 H), 8.12 (d, J=9.2 Hz, 1 H), 7.46 (d, J=9.2 Hz, 1 H), 4.09 (s, 3 H), 4.07 - 4.04 (m, 1 H), 3.94 - 3.88 (m, 1 H), 3.40 (s, 3 H), 2.66 - 2.58 (m, 1 H), 2.25 - 2.21 (m, 1 H), 1 .73 (s, 3 H), 0.96 (d, J=6.0 Hz, 3 H).
LC-MS (m/z) 322.2 (MH+) tR (minutes, method 5) = 1 .46
[a]D 20 +5.33° (c = 0.10, methanol). Stereoisomer 3:
To an ice-cold solution of stereoisomer 3 example 12 (200 mg, 0.650 mmol) in THF (10 mL) was added NaH (60% dispersion in mineral oil) (39 mg, 0.98 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (120 mg, 0.845 mmol) was added at 0 °C. The reaction was stirred at 25 °C for 3 hrs and then H2O (5 mL) was added. THF was removed in vacuo and the residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with H2O (1 0 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by preparative TLC, using dichloromethane/methanol =50/1 , to give stereoisomer 3 of 8-chloro-/V-(2,3-dimethyltetrahydrofuran-3-yl)-7-methoxy-/V- methylquinazolin-4-amine (78 mg, 37%).
1H NMR (CD3OD, 400 MHz): δ 8.61 (s, 1 H), 8.08 (d, J=9.6 Hz, 1 H), 7.48 (d, J=9.6 Hz, 1 H), 4.50 - 4.47 (m, 1 H) 4.1 0 (s, 3 H), 3.95 - 3.91 (m, 1 H), 3.88 - 3.84 (m, 1 H), 3.31 (s, 3 H), 2.67 - 2.62 (m, 1 H), 2.32 - 2.26 (m, 1 H), 1 .65 (s, 3 H), 1 .39 (d, J=6.4 Hz, 3 H).
LC-MS (m/z) 322.2 (MH+) tR (minutes, method 5) = 1 .50 [a]D 20 -49.33° (c = 0.1 0, methanol). Stereoisomer 4: To an ice-cold solution of stereoisomer 4 example 1 2 (200 mg, 0.650 mmol) in THF (1 0 mL) was added NaH (60% dispersion in oil) (39 mg, 0.98 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (1 20 mg, 0.845 mmol) was added. The reaction was stirred at 25°C for 3 hrs. Then H2O (5 mL) was added and THF was removed in vacuo. The residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with H2O (1 0 mL), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by preparative TLC, using dichloromethane/methanol=50/1 , to give stereoisomer 4 of 8-chloro-/V-(2,3- dimethyltetrahydrofuran-3-yl)-7-methoxy-/V-methylquinazolin-4-amine (92 mg, 44%).
1H NMR (CD3OD, 400 MHz): δ 8.62 (s, 1 H), 8.08 (d, J=9.6 Hz, 1 H), 7.48 (d, J=9.6 Hz, 1 H), 4.50 - 4.47 (m, 1 H) 4.1 0 (s, 3 H), 3.95 - 3.91 (m, 1 H), 3.88 - 3.84 (m, 1 H), 3.32 (s, 3 H), 2.67 - 2.62 (m, 1 H), 2.32 - 2.26 (m, 1 H), 1 .65 (s, 3 H), 1 .39 (d, J=7.6 Hz, 3 H).
LC-MS (m/z) 322.2 (MH+) tR (minutes, method 5) = 1 .50 [a]D 20 +33.33° (c = 0.1 0, methanol). Example 14:
8-Chloro-7-methoxy-W-methyl-W-(2-methyltetrahydrofuran-3-yl)quinazolin-4- amine:
Stereoisomer 1 :
To an ice-cold solution of stereoisomer 1 of example 5 (8-chloro-7-methoxy-/V-(2- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (250 mg, 0.851 mmol) in THF (10 mL) was added a 60% suspension of NaH in mineral oil (61 mg, 1 .5 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (181 mg, 1 .28 mmol) was added at 0 °C. After stirring at 30 °C for 3 hrs H2O (5 mL) was added to the mixture. THF was removed in vacuo and the residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with H2O (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by preparative TLC, using dichloromethane/methanol=50/1 , to give stereoisomer 1 of 8-chloro-7- methoxy-/V-methyl-/V-2-methyltetrahydrofuran-3-yl)quinazolin-4-amine (192 mg, 70.
1H NMR (CDCIs, 400MHz): δ 8.75 (s, 1 H), 7.92 (d, J=8.8 Hz, 1 H), 7.17 (d, J=9.6 Hz, 1 H), 4.82 - 4.76 (m, 1 H), 4.18 (q, J=6.4 Hz, 1 H), 4.08 (s, 3 H), 4.05 - 4.02 (m, 2 H), 3.29 (s, 3 H), 2.54 - 2.49 (m, 1 H), 2.18 - 2.1 1 (m, 1 H), 1 .28 (d, J=6.0 Hz, 3 H).
LC-MS (m/z) 308.1 (MH+) tR (minutes, method 1 ) = 1 .96 [a]D 20 -46.00° (c = 0.10, methanol). Stereoisomer 2:
To an ice-cold solution of stereoisomer 2 of example 5 (8-chloro-7-methoxy-/V-(2- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (250 mg, 0.851 mmol) in THF (10 mL) was added a 60% suspension in mineral oil of NaH (61 mg, 1 .5 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (181 mg, 1 .28 mmol) was added. The reaction was stirred at 30 °C for 3 hrs before addition of H2O (5 mL). THF was removed in vacuo and the residue was extracted with dichloromethane (2x20 ml_). The combined organic phases were washed with H2O (1 0 ml_), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by preparative TLC, using dichloromethane/methanol=50/1 , to give stereoisomer 2 of 8-chloro-7- methoxy-/V-methyl-/V-(-2-methyltetrahydrofuran-3-yl)quinazolin-4-amine (21 7 mg, 80%).
1H NMR (CDCIs, 400 MHz): δ 8.70 (s, 1 H), 7.95 (d, J=9.6 Hz, 1 H), 7.14 (d, J=9.6 Hz, 1 H), 5.47 - 5.42 (m, 1 H), 4.20 - 4.1 7 (m, 1 H), 4.07 (s, 3 H), 4.05 - 4.02 (m, 2 H), 3.73 (q, J=8.8 Hz, 1 H), 3.38 (s, 3 H), 2.47 - 2.42 (m, 1 H), 2.33 - 2.30 (m, 1 H), 1 .28 (d, J=6.4 Hz, 3 H).
LC-MS (m/z) 308.1 (MH+) tR (minutes, method 1 ) = 1 .94
[a]D 20 -48.00° (c = 0.1 0, methanol).
Stereoisomer 3:
To an ice-cold solution of stereoisomer 3 of example 5 (8-chloro-7-methoxy-/V-(2- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (160 mg, 0.545 mmol) in THF (10 ml_) was added a 60% suspension of NaH in mineral oil (39 mg, 0.98. mmol) and the mixture was stirred at 0 °C for 30 min. Mel (1 1 6 mg, 0.81 7 mmmol) was added at 0°C. The reaction was stirred at 30 °C for 3 hrs and then H2O (5 ml_) was added. THF was removed in vacuo and the residue was extracted with dichloromethane (2x20 ml_). The combined organic phases were washed with H2O (1 0 ml_), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by preparative TLC, using dichloromethane/methanol=50/1 ) to give stereoisomer 3 of 8- chloro-7-methoxy-/V-methyl-/V-(-2-methyltetrahydrofuran-3-yl)quinazolin-4-amine
1 39 mg (81 %). 1H NMR (CDCIs, 400 MHz): δ 8.70 (s, 1 H), 7.95 (d, J=9.6 Hz, 1 H), 7.14 (d, J=9.2 Hz, 1 H), 5.47 - 5.42 (m, 1 H), 4.20 - 4.1 6 (m, 1 H), 4.07 (s, 3 H), 4.05 - 4.02 (m, 2 H), 3.75 - 3.73 (m, 1 H), 3.38 (s, 3 H), 2.47 - 2.42 (m, 1 H), 2.34 - 2.30 (m, 1 H), 1 .28 (d, J=6.0 Hz, 3 H).
LC-MS (m/z) 308.1 (MH+) tR (minutes, method 1 ) = 1 .96 [a]D M +52.67° (c = 0.10, methanol). Stereoisomer 4:
To an ice-cold solution of stereoisomer 4 of example 5 (8-chloro-7-methoxy-/V-(2- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (200 mg, 0.681 mmol) in THF (10 mL) was added a 60% suspension of NaH in mineral oil (49 mg, 1 .2 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (145 mg, 1 .02 mmol) was added. The reaction was stirred at 30 °C for 3 hrs and then H2O (5 mL) was added. THF was removed in vacuo and the residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with H2O (10 mL), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by preparative TLC, dichloromethane/methanol=50/1 , to give stereoisomer 4 of 8-chloro-7-methoxy- A/-methyl-/V-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine 184 mg (85%).
1H NMR (CDCI3, 400 MHz): δ 8.75 (s, 1 H), 7.92 (d, J=9.2 Hz, 1 H), 7.17 (d, J=9.2 Hz, 1 H), 4.82 - 4.76 (m, 1 H), 4.19 - 4.16 (m, 1 H), 4.08 (s, 3 H), 4.05 - 4.02 (m, 2 H), 3.29 (s, 3 H), 2.54 - 2.49 (m, 1 H), 2.18 - 2.1 1 (m, 1 H), 1 .28 (d, J=6.4 Hz, 3 H).
LC-MS (m/z) 308.1 (MH+) tR (minutes, method 1 ) = 1 .94
[a]D 20 +35.33° (c = 0.10, methanol).
Example 15
8-Fluoro-7-methoxy-W-methyl-W-(3-methyltetrahydrofuran-3-yl)quinazolin-4- amine:
Stereoisomer 1 : To solution of stereoisomer 1 of example 1 (8-fluoro-7-methoxy-/V-(3- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (200 mg, 0.721 mmol) in THF (4 mL) was added a 60% suspension of NaH in mineral oil (43 mg, 1 .1 mmol) at 0 °C. After stirring for 30 min the reaction was heated to 20 °C. Mel (154 mg, 1 .08 mmol) was added and the reaction was stirred for 12 hrs. The reaction was quenched with sat. aq. NH CI (0.5 mL) and concentrated in vacuo. The residue was diluted with dichloromethane (20 mL), washed with brine (10 mL), dried, and concentrated in vacuo. The crude product was purified by preparative TLC, using ethyl acetate, to give stereoisomer 1 of 8-fluoro-7-methoxy-/V-methyl-/V-(3-methyltetrahydrofuran-3- yl)quinazolin-4-amine 150 mg (70%).
1H NMR (CDCIs, 400 MHz): δ 8.65 (s, 1 H), 7.73 (dd, J = 9.6, 2.0 Hz, 1 H), 7.19 (dd, J = 9.6, 8.0 Hz, 1 H), 4.35 (d, J = 8.8 Hz, 1 H), 4.07 (s, 3H), 4.02-3.88 (m, 3H), 3.31 (s, 3H), 2.41 -2.35 (m, 1 H), 2.28-2.24 (m, 1 H), 1 .71 (s, 3H).
LC-MS (m/z) 292.1 (MH+) tR (minutes, method 1 ) = 1 .83 [a]D 20 +38.33° (c = 0.10, methanol).
Stereoisomer 2:
To a solution of stereoisomer 2 of example 1 (8-fluoro-7-methoxy-/V-(3- methyltetrahydrofuran-3-yl)quinazolin-4-amine) (200 mg, 0.721 mmol) in THF (4 mL) was added a 60% suspension in mineral oil NaH (43 mg, 1 .1 mmol) at 0 °C and the reaction was stirred for 30 min before being heated at 20 °C. Mel (154 mg, 1 .08 mmol) was added and stirring continued for 12 hrs. The solution was quenched with sat. aq. NH CI (1 mL) and concentrated in vacuo. The residue was diluted with dichloromethane (20 mL), washed with brine (3^8 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by preparative TLC, using ethyl acetate, to give stereoisomer 2 of 8-fluoro-7-methoxy-/V-methyl-/V-(3- methyltetrahydrofuran-3-yl)quinazolin-4-amine 160 mg (75%).
1H NMR (CDCI3, 400 MHz): δ 8.65 (s, 1 H), 7.73 (dd, J = 9.6,1 .6 Hz, 1 H), 7.18 (dd, J = 9.2, 8.0 Hz, 1 H), 4.35 (d, J = 9.2 Hz, 1 H), 4.02 (s, 3H), 4.00-3.88 (m, 3H), 3.31 (s, 3H), 2.43-2.35 (m, 1 H), 2.28-2.24 (m, 1 H), 1 .71 (s, 3H). LC-MS (m/z) 292.1 (MH+) tR (minutes, method 1 ) = 1 .83 -30.00° (c = 0.10, methanol).
Example 16
8-Fluoro-7-methoxy-W-(tetrahydrofuran-3-yl)quinazolin-4-amine:
A solution of 4-chloro-8-fluoro-7-methoxyquinazoline (400 mg, 1 .88 mmol) tetrahydrofuran-3-amine (192 mg, 2.26 mmol) and diisopropylethylamine (486 mg, 3.76 mmol) in DMF (10 mL) was stirred at 100 °C for 3 hrs. The reaction mixture was concentrated in vacuo and purified by flash chromatography on silica gel using a gradient dichloromethane/ethyl acetate to give 8-fluoro-7-methoxy-/V- (tetrahydrofuran-3-yl)quinazolin-4-amine 360 mg (72%).
The racemate of 8-fluoro-7-methoxy-/V-(tetrahydrofuran-3-yl)quinazolin-4-amine (360 mg) was purified by SFC (Column: AD-H (250mm*30mm,5um)) separation and numbered according to the order of elution:
Stereoisomer 1 :
150 mg (42%)
1H NMR (CDCI3, 400 MHz): δ 8.66 (s, 1 H), 7.48 (dd, J = 9.2, 1 .6 Hz, 1 H), 7.22-7.18 (m, 1 H), 5.86 (d, J = 6.4 Hz, 1 H), 4.99-4.94 (m, 1 H), 4.05-3.99 (m, 1 H), 3.99 (s, 3H), 3.97-3.96 (m, 1 H), 3.91 -3.86 (m, 2H), 2.49-2.43 (m, 1 H), 2.05-2.00 (m, 2H).
LC-MS (m/z) 264.1 (MH+) tR (minutes, method 1 ) = 1 .72 [a]D +29.33° (c = 0.10, methanol). Stereoisomer 2:
150 mg (42%)
1H NMR (CDCIs, 400 MHz): δ 8.66 (s, 1 H), 7.48 (d, J = 8.8 Hz, 1 H), 7.22-7.18 (m, 1 H), 5.86 (d, J = 6.4 Hz, 1 H), 4.99-4.94 (m, 1 H), 4.05-4.00 (m, 1 H), 4.00 (s, 3H), 3.97-3.96 (m, 1 H), 3.91 -3.88 (m, 2H), 2.49-2.44 (m, 1 H), 2.05-2.00 (m, 2H).
LC-MS (m/z) 264.1 (MH+) tR (minutes, method 1 ) = 1 .72 [a]D 20 -34.67° (c = 0.10, methanol).
Example 17
/V-(2,3-Dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxyquinazolin-4-amine: To a solution of 4-chloro-8-fluoro-7-methoxyquinazoline (1 .00 g, 4.70 mmol) in DMSO (1 5 mL) was added 2,3-dimethyltetrahydrofuran-3-amine (541 mg, 4.70 mmol) and NaHCO3 (395 mg, 4.70 mmol). The mixture was heated at 1 00 °C for 3 hrs and then cooled to 25 °C. H2O (50 mL) was added and the mixture was extracted with dichloromethane (2x50 mL). The combined organic phases were washed with water (2x50 mL), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel using a gradient of dichloromethane and methanol, to give A/-(2,3-dimethyltetrahydrofuran-3-yl)-8-fluoro- 7-methoxyquinazolin-4-amine 700 mg (51 %). The mixture of all 4 stereoisomers of A/-(2,3-dimethyltetrahydrofuran-3-yl)-8-fluoro-7- methoxyquinazolin-4-amine 2.3 g was purified by SFC (Column : Chiral Pak AD, 5μηη, Daicel Chemical Industries, Ltd 250x30mm I.D).
Stereoisomer 3:
300 mg (13%)
1H NMR (CDCI3, 400 MHz): δ 8.66 (s, 1 H), 7.43-7.41 (m, 1 H), 7.21 -7.17 (m, 1 H), 5.74 (s, 1 H), 4.05 (s, 3H), 3.92-3.85 (m, 3H), 2.97-2.91 (m, 1 H), 2.10-2.03 (m, 1 H), 1 .71 (s, 3H), 1 .36 (d, J = 6.4 Hz, 3H). LC-MS (m/z) 292.1 (MH+) tR (minutes, method 1 ) = 1 .88
[a]D 20 -25.67° (c = 0.10, methanol).
Stereoisomer 4:
300 mg (13%)
1H NMR (CDCI3, 400 MHz): δ 8.64 (s, 1 H), 7.42-7.39 (m, 1 H), 7.19-7.15 (m, 1 H), 5.71 (s, 1 H), 4.02 (s, 3H), 3.89-3.82 (m, 3H), 2.94-2.88 (m, 1 H), 2.08 - 2.01 (m, 1 H), 1 .69 (s, 3H), 1 .33 (d, J = 6.4 Hz, 3H).
LC-MS (m/z) 292.1 (MH+) tR (minutes, method 1 ) = 1 .86
[a]D 20 +27.33° (c = 0.10, methanol)
From the first SFC purification a mixture of stereoisomer 1 and 2 was obtained. This mixture was subjected to a second purification by SFC(Column : Chiral Pak AS, 5μηη, Daicel Chemical Industries, Ltd 250x30mm I.D.) chromatography to yield:
Stereoisomer 2
600 mg (26%)
1H NMR (CDCI3, 400 MHz): δ 8.60 (s, 1 H), 7.45-7.42 (m, 1 H), 7.15-7.1 1 (m, 1 H), 5.63 (s, 1 H), 4.27 (q, J = 6.4 Hz, 1 H), 3.99 (s, 3H), 3.95-3.85 (m, 2H), 2.72-2.66 (m, 1 H), 2.22-2.17 (m, 1 H), 1 .56 (s, 3H), 1 .23 (d, J = 6.4 Hz, 3H). LC-MS (m/z) 292.1 (MH+) tR (minutes, method 1 ) = 1 .90 [a]D 20 +41 .33° (c = 0.10, methanol). Stereoisomer 1 : 600 mg (26%) 1H NMR (CDCI3, 400 MHz): δ 8.60 (s, 1 H), 7.44-7.42 (m, 1 H), 7.16-7.12 (m, 1 H), 5.61 (s, 1 H), 4.27 (q, J = 6.4 Hz, 1 H), 4.00 (s, 3H), 3.99-3.87 (m, 2H), 2.73-2.66 (m, 1 H), 2.22-2.18 (m, 1 H), 1 .57 (s, 3H), 1 .23 (d, J = 6.0 Hz, 3H).
LC-MS (m/z) 292.1 (MH+) tR (minutes, method 1 ) = 1 .89
[a]D 20 -23.67° (c = 0.10, methanol). Example 18
8-Fluoro-7-methoxy-W-methyl-W-(2-methyltetrahydrofuran-3-yl)quinazolin-4- amine
Stereoisomer 1 : To a solution of stereoisomer 2 of example 3 (A/-(2,3-dimethyltetrahydrofuran-3-yl)-8- fluoro-7-methoxyquinazolin-4-amine) (150 mg, 0.540 mmol) in dry THF (5 mL) was added a 60% suspension of NaH in mineral oil (32 mg, 0.81 mmol) at 0 °C under N2. The mixture was stirred at 0 °C for 30 min, then CH3I (92 mg, 0.65 mmol) was added. The reaction was stirred for 2 hrs at 0 °C before addition of sat. aq. NH CI (5 mL). The crude reaction mixture was extracted with ethyl acetate (3x10 mL). The combined organic phases were washed with brine (5 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by flash chromatography using a gradient of petroleum ether and ethyl acetate to give stereoisomer 1 of 8-fluoro-7- methoxy-/V-methyl-/V-(2-methyltetrahydrofuran-3-yl)quinazolin-4-ami 135 mg (86%).
1H NMR (CDCIs, 400 MHz): 5 8.62 (s, 1 H), 7.79 (dd, J = 9.6, 2.0 Hz, 1 H), 7.17-7.13 (m, 1 H), 5.50-5.45 (m, 1 H), 4.20-4.16 (m, 1 H), 4.07 (s, 3H), 4.04-4.03 (m, 1 H), 3.77- 3.71 (m, 1 H), 3.39 (s, 3H), 2.46-2.42 (m, 1 H), 2.33-2.29 (m, 1 H), 1 .29 (d, J = 6.8 Hz, 3H).
LC-MS (m/z) 292.1 (MH+) tR (minutes, method 2) = 1 .80 [a]D 20 +43.00° (c = 0.10, methanol). Stereoisomer 2: To a solution of stereoisomer 1 of example 3 (A/-(2,3-dimethyltetrahydrofuran-3-yl)-8- fluoro-7-methoxyquinazolin-4-amine) (150 mg, 0.540 mmol) in THF (5 mL) was added a 60% suspension of NaH in mineral oil (32 mg, 0.81 mmol) at 0 °C under N2. The mixture was stirred for 30 min at 0 °C, and then methyliodide (92 mg, 0.65 mmol) was added. Stirring was continued for 2 hrs at 0 °C and then sat. aq. NH CI (5 mL) was added. The mixture was extracted with ethyl acetate (3x10 mL). The combined organic phases were washed with brine (5 mL), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of petroleum ether and ethyl acetate to give stereoisomer 2 of 8- fluoro-7-methoxy-/V-methyl-/V-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine 130 mg (82.5%).
1H NMR (CDCI3, 400 MHz): δ 8.67 (s, 1 H), 7.76 (d, J = 9.6 Hz, 1 H), 7.20-7.16 (m, 1 H), 4.83 (brs, 1 H), 4.19-4.16 (m, 1 H), 4.07-4.02 (m, 5H), 3.31 (s, 3H), 2.50 (brs, 1 H), 2.13 (brs, 1 H), 1 .30 (d, J = 6.0 Hz, 3H).
LC-MS (m/z) 292.1 (MH+) tR (minutes, method 2) = 1 .82 [a]D 20 -30.00° (c = 0.10, methanol).
Stereoisomer 3:
To a solution of stereoisomer 3 of example 3 (A/-(2,3-dimethyltetrahydrofuran-3-yl)- 8-fluoro-7-methoxyquinazolin-4-amine) (150 mg, 0.540 mmol) in THF (5 mL) was added a 60% suspension of NaH in mineral oil (32 mg, 0.81 mmol) at 0 °C under N2 and the mixture was stirred for 30 min. Methyliodide (77 mg, 0.54 mmol) was added at 0 °C and stirring was continued for 2 hrs at 0 °C. The reaction was quenched by sat. aq. NH CI (5ml_) and then extracted with ethyl acetate (3x10 ml_). The combined organic phases were washed with brine (5 ml_), dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography using a gradient of petroleum ether and ethyl acetate to give stereoisomer 3 of 8-fluoro-7- methoxy-/V-methyl-/V-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine (1 10 mg (69.8%). 1H NMR (CDCIs, 400 MHz): 5 8.61 (s, 1 H), 7.79 (dd, J = 9.6, 2.0 Hz, 1 H), 7.17-7.13 (m, 1 H), 5.49-5.45 (m, 1 H), 4.21 -4.16 (m, 1 H), 4.06 (s, 3H), 4.04-4.02 (m, 1 H), 3.77- 3.73 (m, 1 H), 3.39 (s, 3H), 2.46-2.42 (m, 1 H), 2.33-2.29 (m, 1 H), 1 .29 (d, J = 6.4 Hz, 3H).
LC-MS (m/z) 292.1 (MH+) tR (minutes, method 2) = 1 .81 [a]D 20 -73.00° (c = 0.10.methanol). Stereoisomer 4:
To a solution of stereoisomer 4 of example 3 (A/-(2,3-dimethyltetrahydrofuran-3-yl)-8- fluoro-7-methoxyquinazolin-4-amine) (150 mg, 0.541 mmol) in THF (5 ml_) was added a 60% suspension of NaH in mineral oil (32 mg, 0.81 mmol) at 0 °C under N2 and the mixture was stirred for 30 min. Then methyliodide (92 mg, 0.65 mmol) stirring was continued for 2 hrs at 0 °C. The reaction was quenched by addition of sat. aq. NH CI (5 ml_). The reaction was extracted with ethyl acetate (3x10 ml_). The combined organic phases were washed with brine (5 ml_), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of petroleum ether and ethyl acetate to give give stereoisomer 4 of 8-fluoro-7-methoxy-/V-methyl-/V-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine 120 mg (76.2%).
1H NMR (CDCI3, 400 MHz): 5 8.66 (s, 1 H), 7.76 (dd, J = 9.6, 2.0 Hz, 1 H), 7.20-7.16 (m, 1 H), 4.86-4.81 (m, 1 H), 4.19-4.14 (m, 1 H), 4.07 (s, 3H), 4.06-4.02 (m, 2H), 3.31 (s, 3H), 2.54-2.48 (m, 1 H), 2.17-2.10 (m, 1 H), 1 .30 (d, J = 6.4 Hz, 3H). LC-MS (m/z) 292.1 (MH+) tR (minutes, method 2) = 1 .82 [a]D 20 +90.33° (c = 0.10, methanol).
Example 19 W-(2,3-Dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxy-W-methylquinazolin-4- amine:
Stereoisomer 1 :
To an ice-cold solution of stereoisomer 3 of example 17 of (A/-(2,3- dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxyquinazolin-4-amine) (200 mg, 0.687 mmol) in THF (10 mL) was added a 60% dispersion of NaH in mineral oil (55 mg, 1 .4 mmol). The mixture was stirred at 0 °C for 30 min and then Mel (146 mg, 1 .03 mmol) was added. The reaction was warmed to 30 °C and stirred for 2 hrs. H2O (5 mL) was added and the THF was removed in vacuo. The residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with H2O (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by preparative TLC, using petroleum ether and ethyl acetate 1/1 , to give stereoisomer 1 of A/-(2,3-dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxy-/V- methylquinazolin-4-amine 127 mg (60.4%)
1H NMR (CDCI3, 400 MHz): 5 8.66 (s, 1 H), 7.71 (dd, J = 9.2, 2.0 Hz, 1 H), 7.21 -7.17 (m, 1 H), 4.81 (q, J = 6.4 Hz, 1 H), 4.06 (s, 3H), 4.04-4.01 (m, 1 H), 3.94-3.87 (m, 1 H), 3.31 (s, 3H), 2.48-2.40 (m, 1 H), 2.17-2.13 (m, 1 H), 1 .71 (s, 3H), 0.93 (d, J = 6.4 Hz, 3H). LC-MS (m/z) 306.2 (MH+) tR (minutes, method 1 ) = 1 .89 [a]D 20 -8.00° (c = 0.10, methanol).
Stereoisomer 2: To an ice-cold solution of stereoisomer 2 of example 17 (A/-(2,3- dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxyquinazolin-4-amine) (200 mg, 0.687 mmol) in THF (10 mL) was added a 60% suspension of NaH in mineral oil (55 mg,
1 .3 mmol). The reaction was stirred at 0 °C for 30 min and then Mel (146 mg, 1 .03 mmol) was added. The reaction was then heated to 30 °C and stirred for 2 hrs. H2O (5 mL) was added to the mixture and THF was removed in vacuo. The residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with H2O (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by preparative TLC, using petroleum ether and ethyl acetate 1/1 to give stereoisomer 2 of A/-(2,3-dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxy-/V- methylquinazolin-4-amine.
70 mg (33%)
1H NMR (CDCI3, 400 MHz): 5 8.72 (s, 1 H), 7.71 (dd, J = 9.6, 2.0 Hz, 1 H), 7.22-7.18 (m, 1 H), 4.38-4.35 (m, 1 H), 4.06 (s, 3H), 3.93-3.89 (m, 1 H), 3.84-3.80 (m, 1 H), 3.22 (s, 3H), 2.54-2.50 (m, 1 H), 2.30-2.25 (m, 1 H), 1 .60 (s, 3H), 1 .37 (d, J = 6.0 Hz, 3H). LC-MS (m/z) 306.2 (MH+) tR (minutes, method 1 ) = 1 .93
[a]D 20 +38.00° (c = 0.10, methanol).
Stereoisomer 3:
To an ice-cold solution of stereoisomer 4 of example 17 (A/-(2,3- dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxyquinazolin-4-amine) (200 mg, 0.687 mmol) in THF (10 mL) was added a 60% suspension of NaH in mineral oil (55 mg,
1 .4 mmol). The mixture was stirred at 0 °C for 30 min and then methyliodide (146 mg, 1 .03 mmol) was added. The reaction was then heated to 30 °C and stirred for 2 hrs. H2O (5 mL) was added to the mixture and THF was removed in vacuo. The residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with water (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by preparative TLC, using petroleum ether and ethyl acetate 1/1 , to give give stereoisomer 3 of A/-(2,3-dimethyltetrahydrofuran- 3-yl)-8-fluoro-7-methoxy-/V-methylquinazolin-4-amine.
103 mg (49.2%)
1H NMR (CDCI3, 400 MHz): 5 8.66 (s, 1 H), 7.72 (dd, J = 9.2, 1 .6 Hz, 1 H), 7.21 -7.17 (m, 1 H), 4.84-4.80 (m, 1 H), 4.06 (s, 3H), 4.04-4.01 (m, 1 H), 3.94-3.89 (m, 1 H), 3.31 (s, 3H), 2.48-2.40 (m, 1 H), 2.17-2.13 (m, 1 H), 1 .71 (s, 3H), 0.93 (d, J = 6.4 Hz, 3H). LC-MS (m/z) 306.2 (MH+) tR (minutes, method 1 ) = 1 .88
[a]D 20 +13.00° (c = 0.10, methanol).
Stereoisomer 4:
To an ice-cold solution of stereoisomer 1 of example 17 (A/-(2,3- dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxyquinazolin-4-amine) (200 mg, 0.687 mmol) in THF (10 mL) was added a 60% suspension of NaH (55 mg, 1 .4 mmol). The reaction was stirred at 0 °C for 30 min and then methyliodide (146 mg, 1 .03 mmol) was added. The mixture was allowed to warm to 30 °C and stirred for 2 hrs. H2O (5 mL) was added to the mixture and THF was removed in vacuo. The residue was extracted with dichloromethane (2x20 mL). The combined organic phases were washed with H2O (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by preparative TLC, using petroleum ether and ethyl acetate=1/1 , to give stereoisomer 4 of A/-(2,3-dimethyltetrahydrofuran-3-yl)-8-fluoro- 7-methoxy-/V-methylquinazolin-4-amine.
73 mg (35%) 1H NMR (CDCI3, 400 MHz): 5 8.72 (s, 1 H), 7.72 (dd, J = 9.2, 2.0 Hz, 1 H), 7.22-7.18 (m, 1 H), 4.39-4.35 (m, 1 H), 4.06 (s, 3H), 3.92-3.89 (m, 1 H), 3.84-3.80 (m, 1 H), 3.22 (s, 3H), 2.54-2.50 (m, 1 H), 2.30-2.25 (m, 1 H), 1 .60 (s, 3H), 1 .37 (d, J = 6.4 Hz, 3H).
LC-MS (m/z) 306.2 (MH+) tR (minutes, method 1 ) = 1 .90 [a]D M -54.33° (c = 0.10, methanol).
PDE1 INHIBITION ASSAY
PDE1A, PDE1 B and PDE1 C assays were performed as follows: the assays was performed in 60 μΙ_ samples containing a fixed amount of the PDE1 enzyml (sufficient to convert 20-25% of the cyclic nucleotide substrate), a buffer (50 mM HEPES pH 7.6; 10 mM MgCI2; 0.02% Tween20), 0.1 mg/ml BSA, 15 nM tritium labelled cAMP and varying amounts of inhibitors. Reactions were initiated by addition of the cyclic nucleotide substrate, and reactions were allowed to proceed for 1 h at room temperature before being terminated through mixing with 20 μΙ_ (0.2 mg) yttrium silicate SPA beads (PerkinElmer). The beads were allowed to settle for 1 h in the dark before the plates were counted in a Wallac 1450 Microbeta counter. The measured signals were converted to activity relative to an uninhibited control (100%) and IC5o values were calculated using XIFit (model 205, IDBS).

Claims

Claims
1. A compound having the structure
Compound (I) wherein
X is halogen, preferably fluorine or chlorine or bromine;
Ri is selected from the group consisting of H and Ci-C3 alkyl, wherein the alkyl optionally may be substituted one, two or three times with fluorine;
R2 is selected from the group consisting of H and Ci-C4 alkyl wherein the Ci-C4 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of phenyl, monocyclic 5- or 6-membered heteroaryl, C3-C6 cycloalkyl, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl; or R2 together with R9 and the atoms connecting them form a saturated five membered ring; R3 is selected from the group consisting of H and C1-C6 alkyl wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of phenyl, monocyclic 5- or 6-membered heteroaryl, C3-C6 cydoalkyi, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl;
R and R5 independently of each other are selected from the group consisting of H, C1-C6 alkyl, C3-C6 cydoalkyi, fluorine, chlorine, hydroxy and alkoxy of the wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of phenyl, monocyclic 5- or 6-membered heteroaryl, C3-C6 cydoalkyi, fluorine, chlorine, and alkoxy of the form -OR10 wherein R 0 is C1-C5 alkyl;
R6 and R7 independently of each other are selected from the group consisting of H and Ci-C6 alkyl wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of C3-C6 cydoalkyi, fluorine, chlorine, and alkoxy of the form wherein R 0 is C1-C5 alkyl;
Rs and R9 independently of each other are selected from the group consisting of H and Ci-C6 alkyl wherein R9, when R9 is a C1-C-6 alkyl, may form a saturated aliphatic five membered ring with R2 wherein the C1-C6 alkyl optionally is substituted one or more times with one or more substituents independently selected from the group consisting of C3-C6 cycloalkyl, fluorine, chlorine, and alkoxy of the form wherein R 0 is C1-C5 alkyl; and pharmaceutically acceptable acid addition salts of Compound I, racemic mixtures of Compound I, or the corresponding enantiomer and/or optical isomer of Compound I, and polymorphic forms of Compound I as well as tautomeric forms of Compound I.
2. The compound according to claim 1 , wherein R2 is H or -CH3.
3. The compound according to claim 1 or 2, wherein at least one of R6 and R7 is H.
4. The compound according to claim 3, wherein both R6 and R7 are H.
5. The compound according to claim 1 , wherein at least four of R3 to R9 are H.
6. The compound according to claim 1 , wherein R2 and R9 form a five- membered saturated aliphatic ring.
7. The compound according to claim 1 , wherein when any of R3, R4 or R5 are alkyl, then at most one of them is substituted at most once with phenyl or monocyclic 5- or 6-membered heteroaryl.
8. The compound of claim 1 , wherein X is fluorine.
9. The compound of claim 1 , wherein X is chlorine.
10. A compound according to claim 1 selected from the group consisting of 8-fluoro-7-methoxy-/V-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine; 8-fluoro-7-methoxy-/V-methyl-/V-(tetrahydrofuran-3-yl)quinazolin-4-amine; 8-chloro-7-methoxy-/V-(tetrahydrofuran-3-yl)quinazolin-4-amine;
8-fluoro-7-methoxy-/V-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine; 8-chloro-7-methoxy-/V-(2-methyltetrahydrofuran-3-yl)quinazolin-4-amine; 8-chloro-7-methoxy-/V-methyl-/V-(tetrahydrofuran-3-yl)quinazolin-4-am
8-chloro-7-methoxy-/V-(3-methyltetrahydrofuran-3-yl)quinazolin-4-amine; cis-4-(8-fluoro-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole; cis-4-(8-chloro-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole; cis-4-(8-bromo-7-methoxyquinazolin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole; 8-chloro-7-methoxy-/V-methyl-/V-(3-methyltetrahydrofuran-3-yl)quinazolin amine;
8-chloro-/V-(2,3-dimethyltetrahydrofuran-3-yl)-7-methoxyquinazolin-4-amine; 8-chloro-/V-(2,3-dimethyltetrahydrofuran-3-yl)-7-methoxy-/V-methylquinazolin- 4-amine;
8-chloro-7-methoxy-/V-methyl-/V-(2-methyltetrahydrofuran-3-yl)quinazolin-4- amine;
8-fluoro-7-methoxy-/V-methyl-/V-(3-methyltetrahydrofuran-3-yl)quinazolin-4- amine;
8-fluoro-7-methoxy-/V-(tetrahydrofuran-3-yl)quinazolin-4-amine;
N-(2,3-dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxyquinazolin-4-amine; 8-fluoro-7-methoxy-/V-methyl-/V-(2-methyltetrahydrofuran-3-yl)quinazolin-4- amine; and
N-(2,3-dimethyltetrahydrofuran-3-yl)-8-fluoro-7-methoxy-/V-methylquinazolin- 4-amine.
1 1 .A pharmaceutical composition comprising the compound of any of claims 1 to 10 and one or more pharmaceutically acceptable carriers or diluents.
12. The compound of any of claims 1 to 10 for use as a medicament.
13. The compound of any of claims 1 to 10 for use in the treatment of ADHD.
EP15713186.3A 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors Active EP3126354B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
RS20200239A RS60017B1 (en) 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors
PL15713186T PL3126354T3 (en) 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors
SI201531112T SI3126354T1 (en) 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors
HRP20200369TT HRP20200369T1 (en) 2014-04-04 2020-03-04 Halogenated quinazolin-thf-amines as pde1 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400194 2014-04-04
PCT/EP2015/056713 WO2015150254A1 (en) 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors

Publications (2)

Publication Number Publication Date
EP3126354A1 true EP3126354A1 (en) 2017-02-08
EP3126354B1 EP3126354B1 (en) 2020-01-22

Family

ID=52779655

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15713186.3A Active EP3126354B1 (en) 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors

Country Status (38)

Country Link
US (2) US10005764B2 (en)
EP (1) EP3126354B1 (en)
JP (1) JP6554116B2 (en)
KR (1) KR20160138084A (en)
CN (2) CN106132953B (en)
AP (1) AP2016009521A0 (en)
AR (1) AR101155A1 (en)
AU (1) AU2015239696B2 (en)
CA (1) CA2943011A1 (en)
CL (1) CL2016002515A1 (en)
CR (1) CR20160463A (en)
CY (1) CY1122784T1 (en)
DK (1) DK3126354T3 (en)
DO (1) DOP2016000263A (en)
EA (1) EA032579B1 (en)
EC (1) ECSP16082599A (en)
ES (1) ES2776359T3 (en)
GE (1) GEP20186920B (en)
GT (1) GT201600213A (en)
HR (1) HRP20200369T1 (en)
IL (1) IL248078B (en)
JO (1) JO3628B1 (en)
LT (1) LT3126354T (en)
MA (1) MA39837B1 (en)
MX (1) MX364519B (en)
PE (1) PE20161380A1 (en)
PH (1) PH12016501938A1 (en)
PL (1) PL3126354T3 (en)
PT (1) PT3126354T (en)
RS (1) RS60017B1 (en)
RU (1) RU2692808C2 (en)
SG (1) SG11201608190YA (en)
SI (1) SI3126354T1 (en)
SV (1) SV2016005297A (en)
TW (1) TWI664178B (en)
UA (1) UA119166C2 (en)
WO (1) WO2015150254A1 (en)
ZA (1) ZA201606566B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3126354T3 (en) 2014-04-04 2020-06-15 H. Lundbeck A/S Halogenated quinazolin-thf-amines as pde1 inhibitors
MX2019007803A (en) 2016-12-28 2019-08-29 Dart Neuroscience Llc Substituted pyrazolopyrimidinone compounds as pde2 inhibitors.
ES2902365T3 (en) 2017-11-27 2022-03-28 Dart Neuroscience Llc Substituted furanopyrimidine compounds as PDE1 inhibitors
CN117105809B (en) * 2023-10-20 2024-05-03 中国农业大学 Benzanilide compound and preparation method and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042058A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
ZA200507979B (en) * 2003-03-03 2007-03-28 Vertex Pharma Inc Quinazolines useful as modulators of ion channels
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
JP2009527542A (en) * 2006-02-23 2009-07-30 ファイザー・プロダクツ・インク Substituted quinazolines as PDE10 inhibitors
US20070265258A1 (en) * 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
BR112012006615A2 (en) * 2009-09-24 2019-09-24 Basf Se amnoquinazoline compounds of formula I, agricultural composition, veterinary composition, plant propagation material method, seeds and use
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
TW201609713A (en) * 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 Quinazolin-THF-amines as PDE1 inhibitors
TW201611834A (en) 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
PE20161407A1 (en) 2014-04-04 2016-12-28 Hoffmann La Roche PYRIDINE 5,6 DISUSTITUTED -2-CARBOXAMIDES AS CANABINOID RECEPTOR AGONISTS
AR099936A1 (en) 2014-04-04 2016-08-31 Sanofi Sa CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
AR099937A1 (en) 2014-04-04 2016-08-31 Sanofi Sa ISOINDOLINONE COMPOUNDS AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
MA39838B1 (en) 2014-04-04 2019-05-31 Pfizer Bicyclic heteroaryl or fused aryl compounds and their use as irak4 inhibitors
JP6654574B2 (en) 2014-04-04 2020-02-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Pyridine-2-amide useful as a CB2 agonist
PL3126354T3 (en) 2014-04-04 2020-06-15 H. Lundbeck A/S Halogenated quinazolin-thf-amines as pde1 inhibitors

Also Published As

Publication number Publication date
SV2016005297A (en) 2016-11-30
DOP2016000263A (en) 2016-11-30
PH12016501938A1 (en) 2017-02-06
US20190144434A1 (en) 2019-05-16
EA032579B1 (en) 2019-06-28
SI3126354T1 (en) 2020-04-30
WO2015150254A1 (en) 2015-10-08
CN106132953B (en) 2019-03-22
AU2015239696A1 (en) 2016-10-06
RU2016138743A (en) 2018-05-07
AU2015239696B2 (en) 2019-10-24
RS60017B1 (en) 2020-04-30
JP6554116B2 (en) 2019-07-31
AR101155A1 (en) 2016-11-30
CR20160463A (en) 2017-03-06
CN106132953A (en) 2016-11-16
SG11201608190YA (en) 2016-10-28
CN109999039A (en) 2019-07-12
GEP20186920B (en) 2018-11-12
CL2016002515A1 (en) 2016-12-16
PT3126354T (en) 2020-03-17
LT3126354T (en) 2020-03-25
PE20161380A1 (en) 2017-01-15
EA201691773A1 (en) 2017-01-30
ES2776359T3 (en) 2020-07-30
DK3126354T3 (en) 2020-03-09
ECSP16082599A (en) 2017-02-24
KR20160138084A (en) 2016-12-02
UA119166C2 (en) 2019-05-10
MA39837B1 (en) 2020-05-29
CY1122784T1 (en) 2021-05-05
IL248078B (en) 2018-11-29
CA2943011A1 (en) 2015-10-08
RU2016138743A3 (en) 2019-01-15
EP3126354B1 (en) 2020-01-22
MX2016012955A (en) 2016-12-07
US20170022186A1 (en) 2017-01-26
JP2017509680A (en) 2017-04-06
US10526319B2 (en) 2020-01-07
HRP20200369T1 (en) 2020-08-07
TWI664178B (en) 2019-07-01
JO3628B1 (en) 2020-08-27
AP2016009521A0 (en) 2016-10-31
GT201600213A (en) 2019-07-29
ZA201606566B (en) 2017-11-29
US10005764B2 (en) 2018-06-26
TW201620901A (en) 2016-06-16
PL3126354T3 (en) 2020-06-15
RU2692808C2 (en) 2019-06-27
MX364519B (en) 2019-04-30

Similar Documents

Publication Publication Date Title
EP3204387B1 (en) Triazolopyrazinones as pde1 inhibitors
US10526319B2 (en) Halogenated quinazolin-THF-amines as PDE1 inhibitors
US10030007B2 (en) Quinazolin-THF-amines as PDE1 inhibitors
US9718832B2 (en) Hexahydrofuropyrroles as PDE1 inhibitors
OA18062A (en) Halogenated quinazolin-THF-amines as PDE1 inhibitors.
OA17911A (en) Quinazolin-THF-amines as PDE1 inhibitors.
OA18257A (en) Triazolopyrazinones as PDE 1 inhibitors.
OA17878A (en) Hexahydrofuropyrroles as PDE1 inhibitors.

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20171017

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230200

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190924

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1226833

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015045962

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20200369T

Country of ref document: HR

Ref country code: FI

Ref legal event code: FGE

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200304

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3126354

Country of ref document: PT

Date of ref document: 20200317

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20200305

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20200122

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20200400614

Country of ref document: GR

Effective date: 20200511

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 39837

Country of ref document: MA

Kind code of ref document: B1

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20200369T

Country of ref document: HR

Payment date: 20200304

Year of fee payment: 6

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 33670

Country of ref document: SK

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E018961

Country of ref document: EE

Effective date: 20200306

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2776359

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200730

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20200369

Country of ref document: HR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015045962

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20201023

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20200369

Country of ref document: HR

Payment date: 20210326

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20210310

Year of fee payment: 7

Ref country code: NL

Payment date: 20210312

Year of fee payment: 7

Ref country code: NO

Payment date: 20210309

Year of fee payment: 7

Ref country code: SM

Payment date: 20210226

Year of fee payment: 7

Ref country code: LT

Payment date: 20210212

Year of fee payment: 7

Ref country code: RO

Payment date: 20210226

Year of fee payment: 7

Ref country code: MC

Payment date: 20210226

Year of fee payment: 7

Ref country code: PT

Payment date: 20210326

Year of fee payment: 7

Ref country code: IE

Payment date: 20210310

Year of fee payment: 7

Ref country code: GR

Payment date: 20210211

Year of fee payment: 7

Ref country code: CZ

Payment date: 20210226

Year of fee payment: 7

Ref country code: FI

Payment date: 20210309

Year of fee payment: 7

Ref country code: CH

Payment date: 20210317

Year of fee payment: 7

Ref country code: EE

Payment date: 20210203

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20210225

Year of fee payment: 7

Ref country code: BG

Payment date: 20210119

Year of fee payment: 7

Ref country code: BE

Payment date: 20210217

Year of fee payment: 7

Ref country code: DK

Payment date: 20210310

Year of fee payment: 7

Ref country code: LV

Payment date: 20210217

Year of fee payment: 7

Ref country code: IS

Payment date: 20210208

Year of fee payment: 7

Ref country code: SI

Payment date: 20210129

Year of fee payment: 7

Ref country code: RS

Payment date: 20210305

Year of fee payment: 7

Ref country code: SE

Payment date: 20210311

Year of fee payment: 7

Ref country code: PL

Payment date: 20210112

Year of fee payment: 7

Ref country code: TR

Payment date: 20210324

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20210215

Year of fee payment: 7

Ref country code: HR

Payment date: 20210326

Year of fee payment: 7

Ref country code: MT

Payment date: 20210324

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20210208

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20210201

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20210224

Year of fee payment: 7

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1226833

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200122

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20210213

Year of fee payment: 8

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20200369

Country of ref document: HR

Effective date: 20220327

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E018961

Country of ref document: EE

Effective date: 20220331

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

Ref country code: DK

Ref legal event code: EBP

Effective date: 20220331

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20220327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220927

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20220401

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 33670

Country of ref document: SK

Effective date: 20220327

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 1226833

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20220331

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20221122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220328

Ref country code: RS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220401

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220328

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221006

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230405

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230328

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231229

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231229

Year of fee payment: 10

Ref country code: GB

Payment date: 20240108

Year of fee payment: 10

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MA

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220328

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240212

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200122